AI in Biotechnology Market by Function (Drug Design & Optimization, Biomarker, SAR; Clinical Trial Design, Data Assessment, RWE, Inventory, Supply Chain, Logistics; Launch, Pricing, Patient Engagement, Adverse Events) and End User - Global Forecast to 2035

icon1
USD USD 22.72 Billion
MARKET SIZE, 2035
icon2
CAGR 18.5%
(2025-2035)
icon3
397
REPORT PAGES
icon4
471
MARKET TABLES

OVERVIEW

AI in Biotechnology Market Overview

Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis

The AI in biotechnology market size is projected to reach USD 22.72 billion by 2035, from USD 4.16 billion in 2025, at a CAGR of 18.5% during the forecast period. This growth is primarily driven by the increasing adoption of AI for drug discovery, precision medicine, and genomics research, coupled with the rising demand for accelerated biopharmaceutical development. The integration of ML algorithms, predictive analytics, and automation tools into biotechnology workflows enhances research efficiency, improves accuracy in biomarker identification, and optimizes therapeutic development. The convergence of AI with cloud computing and big data platforms further supports large-scale data analysis and decision-making, fueling market expansion.

KEY TAKEAWAYS

  • BY REGION
    The North American AI in biotechnology market accounted for a 42.6% revenue share in 2024.
  • BY OFFERING
    By offering, the end-to-end solutions segment is set to register the highest CAGR of 19.9%.
  • BY FUNCTION
    By function, the research & development segment is projected to grow at the highest rate from 2025 to 2035.
  • BY DEPLOYMENT MODE
    By deployment mode, the cloud-based segment is poised to dominate the market.
  • BY END USER
    By end user, pharmaceutical companies accounted for the largest share, 36.2%, in 2024.
  • COMPETITIVE LANDSCAPE
    NVIDIA, Illumina, Inc., and Recursion are key leaders in the global AI in biotechnology market, recognized for their extensive product portfolios, robust data integration capabilities, and strong presence across healthcare ecosystems.

The AI in biotechnology market is steadily expanding, driven by growing investments in digital transformation and the increasing focus on data-driven drug discovery, genomics, and precision medicine in the US and EU. Advances in machine learning, predictive analytics, and automation are enhancing research efficiency, biomarker identification, and therapeutic development. Moreover, strategic collaborations between biotech firms, AI solution providers, and research institutions are fostering innovation and enabling more integrated, scalable, and intelligent biotechnology workflows.

TRENDS & DISRUPTIONS IMPACTING CUSTOMERS' CUSTOMERS

The impact on consumers’ businesses in the AI in biotechnology market stems from evolving research priorities and technological advancements. Pharmaceutical companies, biotechnology firms, and research institutes are the primary end users, and their adoption needs drive AI implementation. Shifts in these trends or disruptions, such as increasing demand for AI-driven drug discovery, predictive analytics, or automation in genomics and precision medicine, directly influence end-user efficiency and productivity, thereby affecting the financial performance of AI solution providers in the biotechnology sector.

AI in Biotechnology Market Disruptions

Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis

MARKET DYNAMICS

Drivers
Impact
Level
  • Rising adoption of AI in precision medicine
  • Growing cross-industry collaborations and partnerships
RESTRAINTS
Impact
Level
  • High implementation costs of AI limit adoption in biotechnology, especially for SMEs and emerging economies
  • Data privacy risks and compliance challenges for AI in biotechnology
OPPORTUNITIES
Impact
Level
  • Surge in biotechnology investments enhances opportunities for AI to accelerate drug discovery innovations
  • Innovation across healthcare, agriculture, and environmental science for global growth
CHALLENGES
Impact
Level
  • Data quality and interpretability issues that hinder AI integration and trustworthiness
  • AI deployment in biotechnology hindered by talent shortages and evolving regulatory challenges

Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis

Driver: Rising adoption of AI in precision medicine

The rising adoption of AI in precision medicine is a key driver of the AI in biotechnology market. By integrating genomic, clinical, pharmaceutical, and lifestyle data, AI enables early disease detection and the development of personalized, effective treatments. AI algorithms can model synthetic patient populations, predict drug responses, and uncover complex interactions between genetics, microbiomes, and environmental factors. These capabilities enhance research accuracy, treatment efficacy, and healthcare efficiency, positioning AI as a transformative force in precision medicine.

Restraint: High implementation costs of AI limit adoption in biotechnology, especially for SMEs and emerging economies

High implementation and maintenance costs remain a major restraint on AI adoption in biotechnology, particularly for SMEs and organizations in emerging economies. Expenses related to licensing, subscriptions, and data management can range from thousands to millions of dollars, making advanced AI solutions financially out of reach for smaller players. Limited IT budgets and prioritization of medical equipment over digital infrastructure further hinder adoption, restricting broader access to AI-driven insights and innovations in the biotechnology sector.

Opportunity: Surge in biotechnology investments enhances opportunities for AI to accelerate drug discovery innovations

The surge in biotechnology investments presents significant opportunities for AI to accelerate drug discovery and innovation. The US, a major biotechnology hub with more than 2,000 private and public companies and 3,429 biotechnology businesses as of 2023 (IBISWorld), is driving this growth. As biotech firms expand, increased funding supports advanced research and the development of novel biopharmaceuticals. AI integration further enhances efficiency in target identification, drug design, and clinical trials, fostering faster and more cost-effective therapeutic innovations.

Challenge: Data quality and interpretability issues that hinder AI integration and trustworthiness

Data quality and interpretability remain major challenges hindering AI integration in biotechnology. Though biotech research produces vast datasets, they are often fragmented and lack standardization, limiting AI’s ability to generate reliable insights. Moreover, the “black box” nature of advanced AI models raises concerns about transparency and trust, particularly in drug discovery and precision medicine. According to the Biocom Institute, over 70% of biotech professionals express concerns about the ethical and interpretability issues of AI, underscoring the need for better data curation and explainable AI systems.

AI in Biotechnology Market: COMMERCIAL USE CASES ACROSS INDUSTRIES

COMPANY USE CASE DESCRIPTION BENEFITS
Provides GPU-accelerated AI platforms for genomics, bioinformatics, and drug discovery Drives research, boosts scalability, and accelerates drug discovery
Uses AI to enhance sequencing data analysis and genome interpretation Improves accuracy, enables faster insights, and supports precision medicine
Combines AI, automation, and imaging for large-scale biological analysis Enables faster discovery, target identification, and efficiency gains
Uses AI and physics-based modeling for virtual screening and drug design Improves prediction accuracy and streamlines compound optimization
AI-enabled biomedical knowledge graph for target identification, drug repurposing, and clinical trial prediction Improved discovery of therapeutic targets, accelerated pipeline development, and increased efficiency in translational research

Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.

MARKET ECOSYSTEM

The AI in biotechnology market ecosystem comprises key players such as NVIDIA (US), Illumina, Inc. (US), Recursion (US), Schrödinger, Inc. (US), and BenevolentAI (UK), which provide advanced AI-driven platforms for drug discovery, genomics analysis, and precision medicine. These companies leverage ML, predictive analytics, and cloud-based solutions to enhance research accuracy, accelerate therapeutic development, and optimize decision-making. End users, including pharmaceutical companies, biotechnology firms, healthcare providers, and CROs, adopt these technologies to improve R&D efficiency, reduce costs, and drive innovation. Collaboration among technology providers, life science organizations, and research institutions continues to strengthen the AI-enabled biotechnology ecosystem and advance personalized healthcare.

AI in Biotechnology Market Ecosystem

Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.

MARKET SEGMENTS

AI in Biotechnology Market Segments

Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis

AI in Biotechnology Market, by Offering

Based on offering, the AI in biotechnology market comprises end-to-end solutions, niche solutions, technologies, and services. The end-to-end solutions segment accounted for the largest share of the market. This growth is attributed to the rising demand for integrated platforms that combine data management, analytics, and automation across the entire biotechnology workflow. These solutions enable seamless collaboration, streamline drug discovery and genomics research, and improve decision-making through real-time insights, making them increasingly preferred by large pharmaceutical and biotechnology companies.

AI in Biotechnology Market, by Function

Based on function, the AI in biotechnology market is segmented into research & development, regulatory compliance, manufacturing & supply chain, launch & commercial, post-marketing surveillance & patient support, and corporate. The research & development segment accounted for the largest share of the market. This is due to the growing use of AI in drug discovery, genomics, and biomarker identification, which significantly accelerates research timelines and enhances accuracy. AI-driven predictive modeling and data analytics also help reduce costs, optimize clinical trial design, and improve the success rate of new drug candidates.

AI in Biotechnology Market, by Deployment Mode

Based on deployment mode, the market is bifurcated into cloud-based and on-premise. The cloud-based segment accounted for the largest share of the AI in biotechnology market. This is attributed to the growing preference for scalable, flexible, and cost-efficient solutions that enable real-time data access and collaboration across global research teams. Cloud platforms facilitate seamless integration of AI tools, advanced analytics, and large-scale data storage, supporting faster drug discovery and genomics research while reducing infrastructure and maintenance costs for end users.

AI in Biotechnology Market, by End User

Based on end users, the market is segmented into pharmaceutical companies, biotechnology companies, research institutes & labs, healthcare providers, and contract research organizations (CROs). Pharmaceutical companies accounted for the largest share of the AI in biotechnology market. This is due to their extensive investment in AI-driven drug discovery, precision medicine, and clinical trial optimization, which helps accelerate R&D timelines and reduce costs. The integration of AI enables these companies to improve decision-making, enhance the accuracy of therapeutic development, and maintain a competitive edge in an increasingly data-driven biopharma landscape.

REGION

Asia Pacific to be fastest-growing region in global AI in biotechnology market during forecast period

Asia Pacific is projected to be the fastest-growing region in the global AI in biotechnology market during the forecast period. This is due to increasing investments in biotechnology research, the rising adoption of AI-driven drug discovery and precision medicine, and supportive government initiatives in countries such as China, India, and Japan. The region’s growing number of biotech startups, expanding healthcare infrastructure, and focus on innovation are driving demand for advanced AI solutions, fostering rapid market growth.

AI in Biotechnology Market Region

AI in Biotechnology Market: COMPANY EVALUATION MATRIX

In the AI in biotechnology market matrix, NVIDIA (Star) leads with a strong market presence and a comprehensive AI platform portfolio, driven by high-performance computing, machine learning frameworks, and scalable cloud-based solutions for drug discovery, genomics, and precision medicine. The company’s focus on accelerating AI-driven research, predictive modeling, and large-scale data analytics reinforces its dominant position across pharmaceutical, biotechnology, and healthcare organizations globally. Xtalpi Inc. (Emerging Leader) is gaining traction with innovative AI-powered drug design and predictive chemistry solutions, strengthening its position through niche capabilities and industry-specific offerings that address evolving needs in biopharmaceutical R&D.

AI in Biotechnology Market Evaluation Metrics

Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis

KEY MARKET PLAYERS

MARKET SCOPE

REPORT METRIC DETAILS
Market Size, 2024 (Value) USD 3.51 Billion
Market Forecast, 2035 (Value) USD 22.72 Billion
Growth Rate CAGR of 18.5% from 2025 to 2035
Years Considered 2024–2035
Base Year 2024
Forecast Period 2025–2035
Units Considered Value (USD Million/Billion)
Report Coverage Revenue Forecast, Company Ranking, Competitive Landscape, Growth Factors, and Trends
Segments Covered
  • By Offering:
    • End-to-end Solutions
    • Niche Solutions
    • Technologies
    • Services
  • By Function:
    • Research & Development
    • Regulatory Compliance
    • Manufacturing & Supply Chain
    • Launch & Commercial
    • Post-Market Surveillance & Patient Support
    • Corporate
  • By Deployment Mode:
    • Cloud-based
    • On-premise
  • By End User:
    • Pharmaceutical Companies
    • Biotechnology Companies
    • Research Institutes & Labs
    • Healthcare Providers
    • Contract Research Organizations (CROs)
Regions Covered North America, Europe, Asia Pacific, Latin America, Middle East & Africa

WHAT IS IN IT FOR YOU: AI in Biotechnology Market REPORT CONTENT GUIDE

AI in Biotechnology Market Content Guide

DELIVERED CUSTOMIZATIONS

We have successfully delivered the following deep-dive customizations:

CLIENT REQUEST CUSTOMIZATION DELIVERED VALUE ADDS
Competitive Landscape Mapping Profiles and market share of leading AI vendors in biotechnology (including Insilico Medicine, BenevolentAI, Recursion, Xtalpi), covering AI platforms, data capabilities, drug discovery pipelines, partnerships, AI model types (ML, DL, NLP), and integration with omics data, EHRs, and clinical trials Enables benchmarking of AI capabilities and partnerships, identification of competitive positioning, assessment of market share by application area (drug discovery, diagnostics), and strategic alliances
Market Entry & Growth Strategy Regional and segment-level opportunity assessment (e.g., drug discovery, synthetic biology, precision medicine), analysis of funding trends, startup ecosystem, regulatory support for AI applications, and partnership ecosystems (pharma, academia, tech firms) Accelerates go-to-market planning, de-risks market entry, and supports commercialization, localization, and long-term growth strategies tailored to biotech sub-sectors
Regulatory & Operational Risk Analysis Analysis of AI/ML regulations in biotech across key geographies (FDA’s AI/ML-based SaMD framework, EU AI Act), data privacy laws (HIPAA, GDPR), explainability and validation challenges, and ethical AI deployment in life sciences Supports regulatory readiness, reduces compliance risks, and improves trust and adoption of AI technologies by healthcare providers, biotech firms, and regulatory bodies
Technology Adoption Trends Insights into adoption of AI in biotech R&D, clinical trials, manufacturing, and personalized medicine; analysis of drivers like cloud infrastructure, data interoperability, real-world data, and AI-driven collaboration models Informs innovation strategy, drives targeted investments, and guides product development aligned with evolving AI readiness in biotech institutions

RECENT DEVELOPMENTS

  • January 2025 : NVIDIA introduced Project DIGITS, a personal AI supercomputer powered by the new NVIDIA GB10 Grace Blackwell Superchip. Offering 1 petaflop of AI performance, the system would enable researchers, developers, and students to run models with up to 200 billion parameters on a desktop. Designed for energy efficiency, it supports prototyping, fine-tuning, and deployment of AI applications seamlessly across local systems, cloud, and data centers.
  • January 2025 : Illumina launched a pilot proteomics program to analyze 50,000 UK Biobank samples in collaboration with deCODE Genetics, Standard BioTools, Tecan, GSK, Johnson & Johnson, and Novartis. The program utilized the upcoming Illumina Protein Prep solution to generate high-quality proteomics data, advancing biological insights and facilitating biomarker discovery for conditions like cancer and cardiovascular disease.
  • July 2024 : Schrödinger, Inc. initiated an expansion of its computational platform to predict toxicology risks early in drug discovery. This initiative, funded by a USD 10 million grant from the Bill & Melinda Gates Foundation, aims to enhance drug candidate properties while reducing the risks of development failure associated with off-target protein binding.

 

Table of Contents

Exclusive indicates content/data unique to MarketsandMarkets and not available with any competitors.

TITLE
PAGE NO
1
INTRODUCTION
 
 
 
 
 
53
2
RESEARCH METHODOLOGY
 
 
 
 
 
59
3
EXECUTIVE SUMMARY
 
 
 
 
 
72
4
PREMIUM INSIGHTS
 
 
 
 
 
76
5
MARKET OVERVIEW
AI-driven biotech revolutionizes precision medicine amid cross-industry alliances and rising investment trends.
 
 
 
 
 
80
 
5.1
INTRODUCTION
 
 
 
 
 
 
5.2
MARKET DYNAMICS
 
 
 
 
 
 
 
5.2.1
DRIVERS
 
 
 
 
 
 
 
5.2.1.1
GROWING CROSS-INDUSTRY COLLABORATIONS AND PARTNERSHIPS
 
 
 
 
 
 
5.2.1.2
INCREASING NEED TO REDUCE TIME AND COST OF DRUG DISCOVERY & DEVELOPMENT
 
 
 
 
 
 
5.2.1.3
RISING ADOPTION OF AI IN PRECISION MEDICINE
 
 
 
 
 
 
5.2.1.4
INCREASING INVESTMENTS IN SEMICONDUCTOR CHIPSETS
 
 
 
 
 
5.2.2
RESTRAINTS
 
 
 
 
 
 
 
5.2.2.1
HIGH IMPLEMENTATION COSTS
 
 
 
 
 
 
5.2.2.2
DATA PRIVACY RISKS AND COMPLIANCE CHALLENGES
 
 
 
 
 
5.2.3
OPPORTUNITIES
 
 
 
 
 
 
 
5.2.3.1
RISE OF ADVANCED ANALYTICS AND PREDICTIVE MODELING
 
 
 
 
 
 
5.2.3.2
SURGE IN BIOTECHNOLOGY INVESTMENTS
 
 
 
 
 
 
5.2.3.3
INNOVATIONS ACROSS HEALTHCARE, AGRICULTURE, AND ENVIRONMENTAL SCIENCE
 
 
 
 
 
5.2.4
CHALLENGES
 
 
 
 
 
 
 
5.2.4.1
DATA QUALITY AND INTERPRETABILITY ISSUES
 
 
 
 
 
 
5.2.4.2
SHORTAGE OF QUALIFIED EXPERTS AND EVOLVING REGULATORY CHALLENGES
 
 
 
 
5.3
UNMET NEEDS AND WHITE SPACES
 
 
 
 
 
 
5.4
INTERCONNECTED MARKETS AND CROSS-SECTOR OPPORTUNITIES
 
 
 
 
 
 
5.5
STRATEGIC MOVES BY TIER 1/2/3 PLAYERS
 
 
 
 
 
6
INDUSTRY TRENDS
AI-driven innovations reshape biotech, intensifying competition and altering global pricing dynamics.
 
 
 
 
 
92
 
6.1
EVOLUTION OF AI IN BIOTECHNOLOGY
 
 
 
 
 
 
6.2
PORTER’S FIVE FORCES ANALYSIS
 
 
 
 
 
 
 
6.2.1
BARGAINING POWER OF SUPPLIERS
 
 
 
 
 
 
6.2.2
BARGAINING POWER OF BUYERS
 
 
 
 
 
 
6.2.3
THREAT OF SUBSTITUTES
 
 
 
 
 
 
6.2.4
THREAT OF NEW ENTRANTS
 
 
 
 
 
 
6.2.5
INTENSITY OF COMPETITIVE RIVALRY
 
 
 
 
 
6.3
MACROECONOMICS INDICATORS
 
 
 
 
 
 
 
6.3.1
INTRODUCTION
 
 
 
 
 
 
6.3.2
GDP TRENDS AND FORECAST
 
 
 
 
 
 
6.3.3
TRENDS IN GLOBAL HEALTHCARE IT INDUSTRY
 
 
 
 
 
6.4
VALUE CHAIN ANALYSIS
 
 
 
 
 
 
 
6.5
ECOSYSTEM ANALYSIS
 
 
 
 
 
 
 
6.6
PRICING ANALYSIS
 
 
 
 
 
 
 
 
6.6.1
INDICATIVE PRICING ANALYSIS FOR AI IN BIOTECHNOLOGY, BY OFFERING, BY KEY PLAYERS (2024)
 
 
 
 
 
 
6.6.2
INDICATIVE PRICING OF AI IN BIOTECHNOLOGY, BY REGION
 
 
 
 
 
6.7
KEY CONFERENCES AND EVENTS, 2025–2026
 
 
 
 
 
 
6.8
TRENDS AND DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
 
 
 
 
 
 
6.9
INVESTMENT AND FUNDING SCENARIO
 
 
 
 
 
 
6.10
CASE STUDY ANALYSIS
 
 
 
 
 
 
 
6.10.1
CASE STUDY 1: RAPID TRAINING OF PROTEIN MODELS USING NVIDIA DGX CLOUD
 
 
 
 
 
 
6.10.2
CASE STUDY 2: IMPROVED END-TO-END NGS WORKFLOW FOR EFFICIENT GENETIC VARIANT DETECTION
 
 
 
 
 
 
6.10.3
CASE STUDY 3: ACCELERATED DRUG DISCOVERY WITH GENERATIVE AI AND STREAMLINED WORKFLOWS
 
 
 
 
 
6.11
IMPACT OF 2025 US TARIFF ON AI IN BIOTECHNOLOGY MARKET
 
 
 
 
 
 
 
 
6.11.1
INTRODUCTION
 
 
 
 
 
 
6.11.2
KEY TARIFF RATES
 
 
 
 
 
 
6.11.3
PRICE IMPACT ANALYSIS
 
 
 
 
 
 
6.11.4
IMPACT ON COUNTRIES/REGIONS
 
 
 
 
 
 
 
6.11.4.1
NORTH AMERICA
 
 
 
 
 
 
6.11.4.2
EUROPE
 
 
 
 
 
 
6.11.4.3
ASIA PACIFIC
 
 
 
 
 
6.11.5
IMPACT ON END-USE INDUSTRIES
 
 
 
 
 
 
 
6.11.5.1
PHARMACEUTICAL COMPANIES
 
 
 
 
 
 
6.11.5.2
BIOTECHNOLOGY COMPANIES
 
 
 
 
 
 
6.11.5.3
RESEARCH INSTITUTES AND LABS
 
 
 
 
 
 
6.11.5.4
HEALTHCARE PROVIDERS
 
 
 
 
 
 
6.11.5.5
CONTRACT RESEARCH ORGANIZATIONS (CROS)
 
 
 
7
STRATEGIC DISRUPTION THROUGH TECHNOLOGY, PATENTS, DIGITAL, AND AI ADOPTIONS
Harness AI and emerging tech for disruptive innovation and competitive edge in biotechnology markets.
 
 
 
 
 
109
 
7.1
KEY EMERGING TECHNOLOGIES
 
 
 
 
 
 
 
7.1.1
NATURAL LANGUAGE PROCESSING (NLP)
 
 
 
 
 
 
7.1.2
PREDICTIVE ANALYTICS
 
 
 
 
 
7.2
COMPLEMENTARY TECHNOLOGIES
 
 
 
 
 
 
 
7.2.1
CLOUD COMPUTING
 
 
 
 
 
 
7.2.2
BIG DATA ANALYTICS
 
 
 
 
 
7.3
TECHNOLOGY/PRODUCT ROADMAP
 
 
 
 
 
 
7.4
PATENT ANALYSIS
 
 
 
 
 
 
 
 
7.4.1
PATENT PUBLICATION TRENDS FOR AI IN BIOTECHNOLOGY
 
 
 
 
 
 
7.4.2
JURISDICTION AND TOP APPLICANT ANALYSIS
 
 
 
 
 
7.5
FUTURE APPLICATIONS
 
 
 
 
 
 
 
7.5.1
AI-ENABLED PRECISION DISCOVERY AND MULTI-OMICS INTEGRATION
 
 
 
 
 
 
7.5.2
GENERATIVE BIOLOGY AND AUTOMATED DESIGN OF MOLECULES, PROTEINS, AND GENETIC SYSTEMS
 
 
 
 
 
7.6
IMPACT OF AI/GEN AI ON AI IN BIOTECHNOLOGY MARKET
 
 
 
 
 
 
 
 
7.6.1
INTRODUCTION
 
 
 
 
 
 
7.6.2
TOP USE CASES AND MARKET POTENTIAL
 
 
 
 
 
 
7.6.3
INTERCONNECTED ADJACENT ECOSYSTEM AND IMPACT ON MARKET PLAYERS
 
 
 
 
 
 
 
7.6.3.1
DRUG DISCOVERY AND DEVELOPMENT MARKET
 
 
 
 
 
 
7.6.3.2
GENOMICS AND BIOINFORMATICS MARKET
 
 
 
 
 
 
7.6.3.3
MEDICAL IMAGING & DIAGNOSTICS MARKET
 
 
 
 
 
7.6.4
CLIENTS’ READINESS TO ADOPT GENERATIVE AI IN AI IN BIOTECHNOLOGY MARKET
 
 
 
 
 
 
 
7.6.4.1
USER READINESS
 
 
 
 
 
 
 
 
7.6.4.1.1
PHARMACEUTICAL COMPANIES
 
 
 
 
 
 
7.6.4.1.2
BIOTECHNOLOGY COMPANIES
 
 
 
 
7.6.4.2
IMPACT ASSESSMENT
 
 
 
 
 
 
 
 
7.6.4.2.1
USER A: PHARMACEUTICAL COMPANIES
 
 
 
 
 
 
7.6.4.2.2
USER B: BIOTECHNOLOGY COMPANIES
 
 
 
7.6.5
CASE STUDY ON AI/GENERATIVE AI IMPLEMENTATION
 
 
 
 
 
 
 
7.6.5.1
CASE STUDY 1: ENHANCED OPERATIONS AND REVENUE USING AI-DRIVEN REAL-WORLD DATA ANALYTICS
 
 
 
 
 
 
7.6.5.2
CASE STUDY 2: ADVANCE AI-POWERED TARGET DISCOVERY WITH PROPRIETARY AI PLATFORM
 
 
 
8
REGULATORY LANDSCAPE
Navigate complex global regulations with region-specific insights and key compliance frameworks.
 
 
 
 
 
124
 
8.1
REGIONAL REGULATIONS AND COMPLIANCE
 
 
 
 
 
 
 
8.1.1
NORTH AMERICA
 
 
 
 
 
 
8.1.2
EUROPE
 
 
 
 
 
 
8.1.3
ASIA PACIFIC
 
 
 
 
 
 
8.1.4
LATIN AMERICA
 
 
 
 
 
 
8.1.5
MIDDLE EAST & AFRICA
 
 
 
 
 
8.2
REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
 
 
 
 
 
 
8.3
INDUSTRY STANDARDS
 
 
 
 
 
9
CUSTOMER LANDSCAPE & BUYER BEHAVIOR
Unlock unmet needs and stakeholder influences shaping AI adoption in biotechnology buying decisions.
 
 
 
 
 
131
 
9.1
DECISION-MAKING PROCESS
 
 
 
 
 
 
9.2
INFLUENCE OF STAKEHOLDERS AND BUYING CRITERIA
 
 
 
 
 
 
 
9.2.1
BUYING CRITERIA
 
 
 
 
 
9.3
ADOPTION BARRIERS AND INTERNAL CHALLENGES
 
 
 
 
 
 
9.4
UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES
 
 
 
 
 
 
9.5
END-USER EXPECTATIONS
 
 
 
 
 
10
AI IN BIOTECHNOLOGY MARKET, BY OFFERING
Market Size & Growth Rate Forecast Analysis to 2035 in USD Million | 18 Data Tables
 
 
 
 
 
135
 
10.1
INTRODUCTION
 
 
 
 
 
 
10.2
END-TO-END SOLUTIONS
 
 
 
 
 
 
 
10.2.1
GROWING USE OF ADVANCED ALGORITHMS FOR BETTER PRECISION AND EFFICIENCY TO BOOST MARKET GROWTH
 
 
 
 
 
10.3
NICHE SOLUTIONS
 
 
 
 
 
 
 
10.3.1
ABILITY OF NICHE SOLUTIONS TO ADDRESS SPECIFIC CHALLENGES WITHIN DRUG DISCOVERY TO SUPPORT ADOPTION
 
 
 
 
 
10.4
TECHNOLOGIES
 
 
 
 
 
 
 
10.4.1
ADOPTION OF ADVANCED TECHNOLOGIES FOR DRUG DISCOVERY, PERSONALIZED MEDICINE, AND DATA ANALYTICS TO FUEL GROWTH
 
 
 
 
 
10.5
SERVICES
 
 
 
 
 
 
 
10.5.1
CONSULTING SERVICES
 
 
 
 
 
 
 
10.5.1.1
INCREASING EFFICIENCY OF RESEARCH PROCESSES AND COST SAVINGS TO BOOST ADOPTION
 
 
 
 
 
10.5.2
IMPLEMENTATION SERVICES & ONGOING IT SUPPORT
 
 
 
 
 
 
 
10.5.2.1
INCREASING PRECISION AND EFFICIENCY IN IT SUPPORT SERVICES TO BOOST DEMAND
 
 
 
 
 
10.5.3
TRAINING & EDUCATION SERVICES
 
 
 
 
 
 
 
10.5.3.1
NEED FOR SKILLED TALENT FOR BETTER TRAINING & EDUCATION SERVICES TO DRIVE MARKET
 
 
 
 
 
10.5.4
POST-SALES & MAINTENANCE SERVICES
 
 
 
 
 
 
 
10.5.4.1
COMPLEXITY OF AI SYSTEMS AND NEED FOR IMPROVEMENT IN AI ALGORITHMS TO BOOST MARKET
 
 
 
11
AI IN BIOTECHNOLOGY MARKET, BY FUNCTION
Market Size & Growth Rate Forecast Analysis to 2035 in USD Million | 91 Data Tables
 
 
 
 
 
147
 
11.1
INTRODUCTION
 
 
 
 
 
 
11.2
RESEARCH & DEVELOPMENT
 
 
 
 
 
 
 
11.2.1
DRUG DISCOVERY
 
 
 
 
 
 
 
11.2.1.1
MOLECULAR DESIGN & OPTIMIZATION
 
 
 
 
 
 
 
 
11.2.1.1.1
INCREASED EFFICIENCY IN DRUG DISCOVERY WITH MOLECULAR DESIGN & OPTIMIZATION TO DRIVE MARKET
 
 
 
 
11.2.1.2
BIOMARKER DISCOVERY
 
 
 
 
 
 
 
 
11.2.1.2.1
ABILITY TO ANALYZE LARGE DATA SETS WITH AI-ENABLED BIOMARKER DISCOVERY TO BOOST DEMAND
 
 
 
 
11.2.1.3
STRUCTURE-ACTIVITY RELATIONSHIP (SAR) MODELING
 
 
 
 
 
 
 
 
11.2.1.3.1
IMPROVED DATA ANALYSIS, PREDICTIVE MODELING, AND COMPOUND OPTIMIZATION FOR DRUG CANDIDATES WITH SAR TO FUEL GROWTH
 
 
 
11.2.2
CLINICAL DEVELOPMENT
 
 
 
 
 
 
 
11.2.2.1
TRIAL DESIGN
 
 
 
 
 
 
 
 
11.2.2.1.1
ABILITY OF AI TO IMPROVE TRIAL DESIGN THROUGH SIMULATIONS AND PATIENT STRATIFICATION TO FAVOR MARKET
 
 
 
 
11.2.2.2
SITE SELECTION
 
 
 
 
 
 
 
 
11.2.2.2.1
OPTIMIZED PROCESS OF SELECTING CLINICAL TRIAL SITES TO FUEL GROWTH
 
 
 
 
11.2.2.3
RECRUITMENT
 
 
 
 
 
 
 
 
11.2.2.3.1
ENHANCED PROCESS OF SELECTING AND ENROLLING PARTICIPANTS FOR CLINICAL TRIALS TO DRIVE DEMAND
 
 
 
 
11.2.2.4
CLINICAL DATA ASSESSMENT
 
 
 
 
 
 
 
 
11.2.2.4.1
ABILITY OF CLINICAL DATA ASSESSMENT FOR EFFICIENT AND ACCURATE OF DATA INTERPRETATION TO PROPEL MARKET
 
 
 
 
11.2.2.5
PREDICTIVE TOXICITY & RISK MONITORING
 
 
 
 
 
 
 
 
11.2.2.5.1
ABILITY OF DATA INTEGRATION AND PREDICTIVE MODELING TO CREATE COMPREHENSIVE RISK PROFILES FOR DRUG CANDIDATES
 
 
 
 
11.2.2.6
MONITORING & DRUG ADHERENCE
 
 
 
 
 
 
 
 
11.2.2.6.1
ENHANCED PATIENT COMPLIANCE WITH MONITORING AND DRUG ADHERENCE TO DRIVE MARKET
 
 
 
 
11.2.2.7
REAL-WORLD EVIDENCE (RWE) ANALYSIS
 
 
 
 
 
 
 
 
11.2.2.7.1
ENHANCED SAFETY MONITORING AND ECONOMIC EVALUATION WITH RWE ANALYSIS TO PROPEL GROWTH
 
 
11.3
REGULATORY COMPLIANCE
 
 
 
 
 
 
 
11.3.1
ABILITY OF AI TO ENSURE REGULATORY COMPLIANCE IN CLINICAL TRIALS TO SUPPORT GROWTH
 
 
 
 
 
11.4
MANUFACTURING & SUPPLY CHAIN
 
 
 
 
 
 
 
11.4.1
SUPPLY CHAIN PLANNING
 
 
 
 
 
 
 
11.4.1.1
INCREASING DEMAND FOR REAL-TIME DATA ANALYTICS TO ACCELERATE MARKET GROWTH
 
 
 
 
 
11.4.2
INVENTORY MANAGEMENT
 
 
 
 
 
 
 
11.4.2.1
AUTOMATING STOCK TRACKING AND REPLENISHMENT WITH ADVANCED ANALYTICS TO FUEL MARKET GROWTH
 
 
 
 
 
11.4.3
LOGISTICS OPTIMIZATION
 
 
 
 
 
 
 
11.4.3.1
ABILITY OF AI FOR INCREASED COLLABORATION AND TRANSPARENCY IN BIOTECHNOLOGY LOGISTICS TO AID GROWTH
 
 
 
 
 
11.4.4
DEMAND FORECASTING
 
 
 
 
 
 
 
11.4.4.1
ABILITY TO INTEGRATE DATA FOR A RELIABLE DEMAND FORECAST TO FUEL MARKET GROWTH
 
 
 
 
 
11.4.5
PREDICTIVE MAINTENANCE
 
 
 
 
 
 
 
11.4.5.1
BOOSTING EQUIPMENT RELIABILITY WITH AI-POWERED PREDICTIVE MAINTENANCE TO DRIVE DEMAND
 
 
 
 
 
11.4.6
OTHER MANUFACTURING & SUPPLY CHAIN FUNCTIONS
 
 
 
 
 
11.5
LAUNCH & COMMERCIAL
 
 
 
 
 
 
 
11.5.1
LAUNCH COORDINATION
 
 
 
 
 
 
 
11.5.1.1
INCREASING PRODUCT LAUNCH SUCCESS RATES THROUGH PREDICTIVE ANALYTICS TO BOOST ADOPTION
 
 
 
 
 
11.5.2
PATIENT ENGAGEMENT
 
 
 
 
 
 
 
11.5.2.1
REAL-TIME PATIENT FEEDBACK FOR BETTER HEALTH OUTCOMES TO SUPPORT GROWTH
 
 
 
 
 
11.5.3
MARKETING OPERATIONS
 
 
 
 
 
 
 
11.5.3.1
ENHANCED MARKETING PERFORMANCE WITH AI TO BOOST MARKET GROWTH
 
 
 
 
 
11.5.4
PREDICTIVE PRICING
 
 
 
 
 
 
 
11.5.4.1
ABILITY OF AI TO ENHANCE PRICING ACCURACY TO DRIVE ADOPTION
 
 
 
 
11.6
POST-MARKETING SURVEILLANCE & PATIENT SUPPORT
 
 
 
 
 
 
 
11.6.1
MEDICATION ADHERENCE
 
 
 
 
 
 
 
11.6.1.1
GROWING DEMAND FOR PERSONALIZED TREATMENT PLANS TO DRIVE MARKET
 
 
 
 
 
11.6.2
ADVERSE EVENT REPORTING
 
 
 
 
 
 
 
11.6.2.1
FASTER POST-MARKET SURVEILLANCE AND ENHANCED DRUG SAFETY TO DRIVE DEMAND
 
 
 
 
 
11.6.3
PATIENT MONITORING
 
 
 
 
 
 
 
11.6.3.1
RISE OF REMOTE HEALTHCARE SOLUTIONS TO BOOST MARKET DEMAND
 
 
 
 
 
11.6.4
COMPLIANCE MONITORING
 
 
 
 
 
 
 
11.6.4.1
INCREASING COMPLEXITY OF REGULATORY REQUIREMENTS TO DRIVE ADOPTION
 
 
 
 
 
11.6.5
PATIENT SUPPORT PROGRAMS
 
 
 
 
 
 
 
11.6.5.1
GROWING INTEREST IN PATIENT-CENTERED CARE TO SUPPORT MARKET GROWTH
 
 
 
 
11.7
CORPORATE
 
 
 
 
 
 
 
11.7.1
RISK MANAGEMENT
 
 
 
 
 
 
 
11.7.1.1
RISING EXPENDITURE FOR DRUG DEVELOPMENT TO SUPPORT GROWTH
 
 
 
 
 
11.7.2
COMPLIANCE MONITORING
 
 
 
 
 
 
 
11.7.2.1
STRICT GUIDELINES FOR COMPLEX REGULATORY LANDSCAPES TO AID MARKET GROWTH
 
 
 
 
 
11.7.3
SALES FORCE OPTIMIZATION
 
 
 
 
 
 
 
11.7.3.1
NEED FOR DATA-DRIVEN DECISION-MAKING TO BOOST ADOPTION OF SALES FORCE OPTIMIZATION
 
 
 
 
 
11.7.4
OTHER CORPORATE FUNCTIONS
 
 
 
 
12
AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE
Market Size & Growth Rate Forecast Analysis to 2035 in USD Million | 16 Data Tables
 
 
 
 
 
194
 
12.1
INTRODUCTION
 
 
 
 
 
 
12.2
CLOUD-BASED SOLUTIONS
 
 
 
 
 
 
 
12.2.1
PUBLIC CLOUD
 
 
 
 
 
 
 
12.2.1.1
NEED TO REDUCE DEPENDENCY ON EXPENSIVE ON-PREMISES INFRASTRUCTURE TO BOOST DEMAND
 
 
 
 
 
12.2.2
PRIVATE CLOUD
 
 
 
 
 
 
 
12.2.2.1
NEED FOR ENHANCED SECURITY AND DATA PROTECTION TO PROPEL MARKET GROWTH
 
 
 
 
 
12.2.3
MULTI-CLOUD
 
 
 
 
 
 
 
12.2.3.1
ENHANCED FLEXIBILITY AND COST OPTIMIZATION TO SUPPORT MARKET GROWTH
 
 
 
 
 
12.2.4
HYBRID CLOUD
 
 
 
 
 
 
 
12.2.4.1
COST EFFICIENCY AND FLEXIBILITY OF HYBRID CLOUD MODELS TO FUEL MARKET GROWTH
 
 
 
 
12.3
ON-PREMISES SOLUTIONS
 
 
 
 
 
 
 
12.3.1
BETTER DATA SECURITY, PRIVACY, AND COMPLIANCE WITH REGULATIONS TO FAVOR GROWTH
 
 
 
 
13
AI IN BIOTECHNOLOGY MARKET, BY END USER
Market Size & Growth Rate Forecast Analysis to 2035 in USD Million | 12 Data Tables
 
 
 
 
 
204
 
13.1
INTRODUCTION
 
 
 
 
 
 
13.2
PHARMACEUTICAL COMPANIES
 
 
 
 
 
 
 
13.2.1
INNOVATION AND EFFICIENCY WITH AI INTEGRATION IN DRUG DISCOVERY & DEVELOPMENT TO BOOST ADOPTION
 
 
 
 
 
13.3
BIOTECHNOLOGY COMPANIES
 
 
 
 
 
 
 
13.3.1
ABILITY OF AI-DRIVEN INNOVATIONS FOR BETTER PERSONALIZED MEDICINE AND DRUG DISCOVERY TO SUPPORT MARKET GROWTH
 
 
 
 
 
13.4
RESEARCH INSTITUTES & LABS
 
 
 
 
 
 
 
13.4.1
STRATEGIC INVESTMENTS AND COLLABORATIONS TO PROPEL AI ADVANCEMENTS IN RESEARCH INSTITUTES AND LABS
 
 
 
 
 
13.5
HEALTHCARE PROVIDERS
 
 
 
 
 
 
 
13.5.1
IMPROVED PATIENT OUTCOMES TO SUPPORT ADOPTION
 
 
 
 
 
13.6
CONTRACT RESEARCH ORGANIZATIONS
 
 
 
 
 
 
 
13.6.1
ABILITY OF AI TECHNOLOGIES TO ACCELERATE CLINICAL TRIALS AND IMPROVE PATIENT RECRUITMENT TO FUEL GROWTH
 
 
 
 
14
AI IN BIOTECHNOLOGY MARKET, BY REGION
Comprehensive coverage of 8 Regions with country-level deep-dive of 14 Countries | 636 Data Tables.
 
 
 
 
 
213
 
14.1
INTRODUCTION
 
 
 
 
 
 
14.2
NORTH AMERICA
 
 
 
 
 
 
 
14.2.1
MACROECONOMIC OUTLOOK FOR NORTH AMERICA
 
 
 
 
 
 
14.2.2
US
 
 
 
 
 
 
 
14.2.2.1
US TO DOMINATE NORTH AMERICAN AI IN BIOTECHNOLOGY MARKET DURING STUDY PERIOD
 
 
 
 
 
14.2.3
CANADA
 
 
 
 
 
 
 
14.2.3.1
AVAILABILITY OF ADVANCED FACILITIES AND SHORTER APPROVAL TIMES FOR DRUG CANDIDATES TO DRIVE MARKET
 
 
 
 
14.3
EUROPE
 
 
 
 
 
 
 
14.3.1
MACROECONOMIC OUTLOOK FOR EUROPE
 
 
 
 
 
 
14.3.2
GERMANY
 
 
 
 
 
 
 
14.3.2.1
INCREASED FUNDING IN STARTUPS TO DRIVE UPTAKE OF AI IN BIOTECHNOLOGY
 
 
 
 
 
14.3.3
UK
 
 
 
 
 
 
 
14.3.3.1
INCREASING INVESTMENTS AND GOVERNMENT FUND ALLOCATIONS TO DRIVE MARKET
 
 
 
 
 
14.3.4
FRANCE
 
 
 
 
 
 
 
14.3.4.1
GOVERNMENT INITIATIVES IN FRANCE TO SUPPORT MARKET GROWTH
 
 
 
 
 
14.3.5
ITALY
 
 
 
 
 
 
 
14.3.5.1
GROWING INVESTMENTS TO CREATE OPPORTUNITIES FOR MARKET GROWTH
 
 
 
 
 
14.3.6
SPAIN
 
 
 
 
 
 
 
14.3.6.1
INCREASING NEED FOR PERSONALIZED MEDICINE AND DATA-DRIVEN HEALTHCARE TO INCREASE ADOPTION RATE IN MARKET
 
 
 
 
 
14.3.7
REST OF EUROPE
 
 
 
 
 
14.4
ASIA PACIFIC
 
 
 
 
 
 
 
14.4.1
MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
 
 
 
 
 
 
14.4.2
JAPAN
 
 
 
 
 
 
 
14.4.2.1
ACCELERATING AI-DRIVEN DRUG DISCOVERY AND BIOTECHNOLOGY INNOVATION TO DRIVE JAPANESE MARKET
 
 
 
 
 
14.4.3
CHINA
 
 
 
 
 
 
 
14.4.3.1
RISING FOREIGN INVESTMENTS IN BIOTECHNOLOGY AND BIOPHARMACEUTICALS TO PROPEL MARKET GROWTH
 
 
 
 
 
14.4.4
INDIA
 
 
 
 
 
 
 
14.4.4.1
INCREASING NUMBER OF STARTUPS AND GROWING SUPPORT FROM GOVERNMENT TO PROPEL MARKET GROWTH
 
 
 
 
 
14.4.5
SOUTH KOREA
 
 
 
 
 
 
 
14.4.5.1
SIGNIFICANT ADVANCES IN AI INTEGRATION FOR R&D TO FUEL GROWTH
 
 
 
 
 
14.4.6
AUSTRALIA
 
 
 
 
 
 
 
14.4.6.1
ACCELERATING AI ADOPTION IN AUSTRALIA’S BIOTECH SECTOR TO AUGMENT MARKET GROWTH
 
 
 
 
 
14.4.7
REST OF ASIA PACIFIC
 
 
 
 
 
14.5
LATIN AMERICA
 
 
 
 
 
 
 
14.5.1
MACROECONOMIC OUTLOOK FOR LATIN AMERICA
 
 
 
 
 
 
14.5.2
BRAZIL
 
 
 
 
 
 
 
14.5.2.1
FUNDING OF BIOTECH COMPANIES TO DRIVE BRAZILIAN MARKET GROWTH
 
 
 
 
 
14.5.3
MEXICO
 
 
 
 
 
 
 
14.5.3.1
INVESTMENT INFLOWS AND STRENGTHENING AI-RELATED EDUCATION TO SPUR MARKET GROWTH
 
 
 
 
 
14.5.4
REST OF LATIN AMERICA
 
 
 
 
 
14.6
MIDDLE EAST & AFRICA
 
 
 
 
 
 
 
14.6.1
MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
 
 
 
 
 
 
14.6.2
GCC COUNTRIES
 
 
 
 
 
 
 
14.6.2.1
INCREASE IN HEALTHCARE INVESTMENTS TO SUPPORT MARKET GROWTH
 
 
 
 
 
14.6.3
REST OF MIDDLE EAST & AFRICA
 
 
 
 
15
COMPETITIVE LANDSCAPE
Uncover top AI biotech market leaders' strategies and financial prowess for competitive advantage.
 
 
 
 
 
487
 
15.1
INTRODUCTION
 
 
 
 
 
 
15.2
KEY PLAYER STRATEGY/RIGHT TO WIN
 
 
 
 
 
 
 
15.2.1
OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN AI IN BIOTECHNOLOGY MARKET
 
 
 
 
 
15.3
REVENUE ANALYSIS, 2020–2024
 
 
 
 
 
 
 
15.4
MARKET SHARE ANALYSIS, 2024
 
 
 
 
 
 
 
 
15.4.1
RANKING OF KEY MARKET PLAYERS
 
 
 
 
 
15.5
COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
 
 
 
 
 
 
 
 
15.5.1
STARS
 
 
 
 
 
 
15.5.2
EMERGING LEADERS
 
 
 
 
 
 
15.5.3
PERVASIVE PLAYERS
 
 
 
 
 
 
15.5.4
PARTICIPANTS
 
 
 
 
 
 
15.5.5
COMPANY FOOTPRINT: KEY PLAYERS, 2024
 
 
 
 
 
 
 
15.5.5.1
COMPANY FOOTPRINT
 
 
 
 
 
 
15.5.5.2
REGION FOOTPRINT
 
 
 
 
 
 
15.5.5.3
COMPONENT FOOTPRINT
 
 
 
 
 
 
15.5.5.4
FUNCTION FOOTPRINT
 
 
 
 
 
 
15.5.5.5
END-USER FOOTPRINT
 
 
 
 
15.6
COMPANY EVALUATION MATRIX: START-UPS/SMES, 2023
 
 
 
 
 
 
 
 
15.6.1
PROGRESSIVE COMPANIES
 
 
 
 
 
 
15.6.2
RESPONSIVE COMPANIES
 
 
 
 
 
 
15.6.3
DYNAMIC COMPANIES
 
 
 
 
 
 
15.6.4
STARTING BLOCKS
 
 
 
 
 
 
15.6.5
COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024
 
 
 
 
 
 
 
15.6.5.1
DETAILED LIST OF KEY STARTUPS/SMES
 
 
 
 
 
 
15.6.5.2
COMPETITIVE BENCHMARKING OF KEY STARTUPS/SME PLAYERS
 
 
 
 
15.7
COMPANY VALUATION & FINANCIAL METRICS
 
 
 
 
 
 
 
15.7.1
FINANCIAL METRICS
 
 
 
 
 
 
15.7.2
COMPANY VALUATION
 
 
 
 
 
15.8
BRAND/PRODUCT COMPARISON
 
 
 
 
 
 
 
15.9
COMPETITIVE SCENARIO
 
 
 
 
 
 
 
15.9.1
PRODUCT LAUNCHES & UPGRADES
 
 
 
 
 
 
15.9.2
DEALS
 
 
 
 
 
 
15.9.3
EXPANSIONS
 
 
 
 
16
COMPANY PROFILES
In-depth Company Profiles of Leading Market Players with detailed Business Overview, Product and Service Portfolio, Recent Developments, and Unique Analyst Perspective (MnM View)
 
 
 
 
 
510
 
16.1
KEY PLAYERS
 
 
 
 
 
 
 
16.1.1
NVIDIA CORPORATION
 
 
 
 
 
 
 
16.1.1.1
BUSINESS OVERVIEW
 
 
 
 
 
 
16.1.1.2
PRODUCTS OFFERED
 
 
 
 
 
 
16.1.1.3
RECENT DEVELOPMENTS
 
 
 
 
 
 
 
 
16.1.1.3.1
PRODUCT LAUNCHES
 
 
 
 
 
 
16.1.1.3.2
DEALS
 
 
 
 
16.1.1.4
MNM VIEW
 
 
 
 
 
 
 
 
16.1.1.4.1
RIGHT TO WIN
 
 
 
 
 
 
16.1.1.4.2
STRATEGIC CHOICES
 
 
 
 
 
 
16.1.1.4.3
WEAKNESSES & COMPETITIVE THREATS
 
 
 
16.1.2
ILLUMINA, INC.
 
 
 
 
 
 
16.1.3
RECURSION
 
 
 
 
 
 
16.1.4
SCHRÖDINGER, INC.
 
 
 
 
 
 
16.1.5
BENEVOLENTAI
 
 
 
 
 
 
16.1.6
DATA4CURE, INC.
 
 
 
 
 
 
16.1.7
QIAGEN
 
 
 
 
 
 
16.1.8
INSILICO MEDICINE
 
 
 
 
 
 
16.1.9
DNANEXUS, INC.
 
 
 
 
 
 
16.1.10
TEMPUS
 
 
 
 
 
 
16.1.11
SOPHIA GENETICS
 
 
 
 
 
 
16.1.12
PREDICTIVE ONCOLOGY
 
 
 
 
 
 
16.1.13
DEEP GENOMICS
 
 
 
 
 
 
16.1.14
NUMEDII, INC.
 
 
 
 
 
 
16.1.15
XTALPI INC.
 
 
 
 
 
 
16.1.16
IKTOS
 
 
 
 
 
 
16.1.17
BPGBIO, INC.
 
 
 
 
 
 
16.1.18
EUROFINS DISCOVERY
 
 
 
 
 
16.2
OTHER PLAYERS
 
 
 
 
 
 
 
16.2.1
VERISIM LIFE
 
 
 
 
 
 
16.2.2
LIFEBIT BIOTECH INC.
 
 
 
 
 
 
16.2.3
VALO HEALTH
 
 
 
 
 
 
16.2.4
VERGE GENOMICS
 
 
 
 
 
 
16.2.5
LOGICA
 
 
 
 
 
 
16.2.6
AMERICAN CHEMICAL SOCIETY
 
 
 
 
 
 
16.2.7
AGANITHA AI INC.
 
 
 
 
17
APPENDIX
 
 
 
 
 
585
 
17.1
DISCUSSION GUIDE
 
 
 
 
 
 
17.2
KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
 
 
 
 
 
 
17.3
CUSTOMIZATION OPTIONS
 
 
 
 
 
 
17.4
RELATED REPORTS
 
 
 
 
 
 
17.5
AUTHOR DETAILS
 
 
 
 
 
LIST OF TABLES
 
 
 
 
 
 
 
TABLE 1
AI IN BIOTECHNOLOGY MARKET: INCLUSIONS & EXCLUSIONS
 
 
 
 
 
 
TABLE 2
EXCHANGE RATES UTILIZED FOR CONVERSION TO USD
 
 
 
 
 
 
TABLE 3
AI IN BIOTECHNOLOGY MARKET: RESEARCH ASSUMPTIONS
 
 
 
 
 
 
TABLE 4
AI IN BIOTECHNOLOGY MARKET: RISK ASSESSMENT
 
 
 
 
 
 
TABLE 5
AI IN BIOTECHNOLOGY MARKET: IMPACT ANALYSIS OF MARKET DYNAMICS
 
 
 
 
 
 
TABLE 6
INDICATIVE LIST OF COLLABORATIONS AND PARTNERSHIPS IN AI IN BIOTECHNOLOGY MARKET, 2022−2025
 
 
 
 
 
 
TABLE 7
TABLE AI IN BIOTECHNOLOGY MARKET: UNMET NEEDS
 
 
 
 
 
 
TABLE 8
AI IN BIOTECHNOLOGY MARKET: PORTER’S FIVE FORCES ANALYSIS
 
 
 
 
 
 
TABLE 9
FIGURE 5 AI IN BIOTECHNOLOGY MARKET: ROLE OF COMPANIES IN ECOSYSTEM
 
 
 
 
 
 
TABLE 10
TABLE INDICATIVE PRICING ANALYSIS FOR AI IN BIOTECHNOLOGY OFFERINGS, BY KEY PLAYER, 2024 (USD)
 
 
 
 
 
 
TABLE 11
TABLE INDICATIVE PRICING ANALYSIS FOR AI IN BIOTECHNOLOGY, BY REGION (2024)
 
 
 
 
 
 
TABLE 12
AI IN BIOTECHNOLOGY MARKET: KEY CONFERENCES AND EVENTS, 2025–2026
 
 
 
 
 
 
TABLE 13
US ADJUSTED RECIPROCAL TARIFF RATES
 
 
 
 
 
 
TABLE 14
JURISDICTION ANALYSIS OF TOP APPLICANT COUNTRIES, 2015–2025
 
 
 
 
 
 
TABLE 15
TABLE AI IN BIOTECHNOLOGY MARKET: LIST OF PATENTS/PATENT APPLICATIONS, 2022–2025
 
 
 
 
 
 
TABLE 16
REGULATORY SCENARIO OF NORTH AMERICA
 
 
 
 
 
 
TABLE 17
REGULATORY SCENARIO OF EUROPE
 
 
 
 
 
 
TABLE 18
REGULATORY SCENARIO OF ASIA PACIFIC
 
 
 
 
 
 
TABLE 19
REGULATORY SCENARIO OF LATIN AMERICA
 
 
 
 
 
 
TABLE 20
REGULATORY SCENARIO OF MIDDLE EAST & AFRICA
 
 
 
 
 
 
TABLE 21
TABLE NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
 
 
 
 
 
 
TABLE 22
TABLE EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
 
 
 
 
 
 
TABLE 23
TABLE ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
 
 
 
 
 
 
TABLE 24
TABLE REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
 
 
 
 
 
 
TABLE 25
INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF TOP THREE END USERS (%)
 
 
 
 
 
 
TABLE 26
KEY BUYING CRITERIA FOR TOP THREE END USERS
 
 
 
 
 
 
TABLE 27
UNMET NEEDS IN AI IN BIOTECHNOLOGY MARKET
 
 
 
 
 
 
TABLE 28
TABLE END-USER EXPECTATIONS IN AI IN BIOTECHNOLOGY MARKET
 
 
 
 
 
 
TABLE 29
AI IN BIOTECHNOLOGY MARKET, BY OFFERING, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 30
AI IN BIOTECHNOLOGY MARKET, BY OFFERING, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 31
AI IN BIOTECHNOLOGY MARKET FOR END-TO-END SOLUTIONS, BY REGION, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 32
AI IN BIOTECHNOLOGY MARKET FOR END-TO-END SOLUTIONS, BY REGION, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 33
AI IN BIOTECHNOLOGY MARKET FOR NICHE SOLUTIONS, BY REGION, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 34
AI IN BIOTECHNOLOGY MARKET FOR NICHE SOLUTIONS, BY REGION, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 35
AI IN BIOTECHNOLOGY MARKET FOR TECHNOLOGIES, BY REGION, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 36
AI IN BIOTECHNOLOGY MARKET FOR TECHNOLOGIES, BY REGION, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 37
AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY REGION, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 38
AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY REGION, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 39
CONSULTING SERVICES MARKET, BY REGION, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 40
CONSULTING SERVICES MARKET, BY REGION, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 41
IMPLEMENTATION SERVICES & ONGOING IT SUPPORT MARKET, BY REGION, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 42
IMPLEMENTATION SERVICES & ONGOING IT SUPPORT MARKET, BY REGION, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 43
TRAINING AND EDUCATION SERVICES MARKET, BY REGION, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 44
TRAINING AND EDUCATION SERVICES MARKET, BY REGION, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 45
POST-SALES AND MAINTENANCE SERVICES MARKET, BY REGION, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 46
AI IN BIOTECHNOLOGY MARKET FOR POST-SALES AND MAINTENANCE SERVICES, BY REGION, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 47
AI IN BIOTECHNOLOGY MARKET, BY FUNCTION, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 48
AI IN BIOTECHNOLOGY MARKET, BY FUNCTION, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 49
AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT, BY TYPE, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 50
AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT, BY TYPE, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 51
AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT, BY REGION, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 52
AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT, BY REGION, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 53
EXAMPLES OF AI TOOLS USED IN DRUG DISCOVERY
 
 
 
 
 
 
TABLE 54
DRUG DISCOVERY MARKET, BY TYPE, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 55
DRUG DISCOVERY MARKET, BY TYPE, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 56
DRUG DISCOVERY MARKET, BY REGION, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 57
DRUG DISCOVERY MARKET, BY REGION, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 58
MOLECULAR DESIGN & OPTIMIZATION MARKET, BY REGION, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 59
MOLECULAR DESIGN & OPTIMIZATION MARKET, BY REGION, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 60
BIOMARKER DISCOVERY MARKET, BY REGION, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 61
BIOMARKER DISCOVERY MARKET, BY REGION, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 62
STRUCTURE-ACTIVITY RELATIONSHIP (SAR) MODELING MARKET, BY REGION, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 63
STRUCTURE-ACTIVITY RELATIONSHIP (SAR) MODELING MARKET, BY REGION, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 64
CLINICAL DEVELOPMENT MARKET, BY TYPE, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 65
CLINICAL DEVELOPMENT MARKET, BY TYPE, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 66
CLINICAL DEVELOPMENT MARKET, BY REGION, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 67
CLINICAL DEVELOPMENT MARKET, BY REGION, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 68
TRIAL DESIGN MARKET, BY REGION, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 69
TRIAL DESIGN MARKET, BY REGION, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 70
SITE SELECTION MARKET, BY REGION, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 71
SITE SELECTION MARKET, BY REGION, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 72
RECRUITMENT MARKET, BY REGION, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 73
RECRUITMENT MARKET, BY REGION, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 74
CLINICAL DATA ASSESSMENT MARKET, BY REGION, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 75
CLINICAL DATA ASSESSMENT MARKET, BY REGION, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 76
PREDICTIVE TOXICITY & RISK MONITORING MARKET, BY REGION, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 77
PREDICTIVE TOXICITY & RISK MONITORING MARKET, BY REGION, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 78
MONITORING & DRUG ADHERENCE MARKET, BY REGION, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 79
MONITORING & DRUG ADHERENCE MARKET, BY REGION, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 80
REAL-WORLD EVIDENCE (RWE) ANALYSIS MARKET, BY REGION, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 81
REAL-WORLD EVIDENCE (RWE) ANALYSIS MARKET, BY REGION, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 82
AI IN BIOTECHNOLOGY MARKET FOR REGULATORY COMPLIANCE, BY REGION, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 83
AI IN BIOTECHNOLOGY MARKET FOR REGULATORY COMPLIANCE, BY REGION, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 84
AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN, BY TYPE, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 85
AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN, BY TYPE, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 86
AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN, BY REGION, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 87
AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN, BY REGION, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 88
SUPPLY CHAIN PLANNING MARKET, BY REGION, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 89
SUPPLY CHAIN PLANNING MARKET, BY REGION, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 90
INVENTORY MANAGEMENT MARKET, BY REGION, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 91
INVENTORY MANAGEMENT MARKET, BY REGION, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 92
LOGISTICS OPTIMIZATION MARKET, BY REGION, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 93
LOGISTICS OPTIMIZATION MARKET, BY REGION, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 94
DEMAND FORECASTING MARKET, BY REGION, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 95
DEMAND FORECASTING MARKET, BY REGION, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 96
PREDICTIVE MAINTENANCE MARKET, BY REGION, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 97
PREDICTIVE MAINTENANCE MARKET, BY REGION, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 98
OTHER MANUFACTURING & SUPPLY CHAIN FUNCTIONS MARKET, BY REGION, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 99
OTHER MANUFACTURING & SUPPLY CHAIN FUNCTIONS MARKET, BY REGION, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 100
AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL, BY TYPE, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 101
AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL, BY TYPE, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 102
AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL, BY REGION, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 103
AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL, BY REGION, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 104
LAUNCH COORDINATION MARKET, BY REGION, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 105
LAUNCH COORDINATION MARKET, BY REGION, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 106
PATIENT ENGAGEMENT MARKET, BY REGION, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 107
PATIENT ENGAGEMENT MARKET, BY REGION, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 108
MARKETING OPERATIONS MARKET, BY REGION, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 109
MARKETING OPERATIONS MARKET, BY REGION, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 110
PREDICTIVE PRICING MARKET, BY REGION, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 111
PREDICTIVE PRICING MARKET, BY REGION, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 112
AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT, BY TYPE, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 113
AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT, BY TYPE, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 114
AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT, BY REGION, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 115
AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT, BY REGION, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 116
MEDICATION ADHERENCE MARKET, BY REGION, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 117
MEDICATION ADHERENCE MARKET, BY REGION, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 118
ADVERSE EVENT REPORTING MARKET, BY REGION, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 119
ADVERSE EVENT REPORTING MARKET, BY REGION, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 120
PATIENT MONITORING MARKET, BY REGION, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 121
PATIENT MONITORING MARKET, BY REGION, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 122
COMPLIANCE MONITORING MARKET, BY REGION, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 123
COMPLIANCE MONITORING MARKET, BY REGION, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 124
PATIENT SUPPORT PROGRAMS MARKET, BY REGION, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 125
PATIENT SUPPORT PROGRAMS MARKET, BY REGION, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 126
AI IN BIOTECHNOLOGY MARKET FOR CORPORATE, BY TYPE, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 127
AI IN BIOTECHNOLOGY MARKET FOR CORPORATE, BY TYPE, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 128
AI IN BIOTECHNOLOGY MARKET FOR CORPORATE, BY REGION, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 129
AI IN BIOTECHNOLOGY MARKET FOR CORPORATE, BY REGION, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 130
RISK MANAGEMENT MARKET, BY REGION, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 131
RISK MANAGEMENT MARKET, BY REGION, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 132
COMPLIANCE MONITORING MARKET, BY REGION, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 133
COMPLIANCE MONITORING MARKET, BY REGION, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 134
SALES FORCE OPTIMIZATION MARKET, BY REGION, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 135
SALES FORCE OPTIMIZATION MARKET, BY REGION, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 136
OTHER CORPORATE FUNCTIONS MARKET, BY REGION, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 137
OTHER CORPORATE FUNCTIONS MARKET, BY REGION, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 138
AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 139
AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 140
AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 141
AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 142
AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY REGION, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 143
AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY REGION, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 144
PUBLIC CLOUD MARKET, BY REGION, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 145
PUBLIC CLOUD MARKET, BY REGION, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 146
PRIVATE CLOUD MARKET, BY REGION, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 147
PRIVATE CLOUD MARKET, BY REGION, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 148
MULTI CLOUD MARKET, BY REGION, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 149
MULTI CLOUD MARKET, BY REGION, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 150
HYBRID CLOUD MARKET, BY REGION, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 151
HYBRID CLOUD MARKET, BY REGION, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 152
AI IN BIOTECHNOLOGY MARKET FOR ON-PREMISES SOLUTIONS, BY REGION, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 153
AI IN BIOTECHNOLOGY MARKET FOR ON-PREMISES SOLUTIONS, BY REGION, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 154
AI IN BIOTECHNOLOGY MARKET, BY END USER, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 155
AI IN BIOTECHNOLOGY MARKET, BY END USER, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 156
AI IN BIOTECHNOLOGY MARKET FOR PHARMACEUTICAL COMPANIES, BY REGION, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 157
AI IN BIOTECHNOLOGY MARKET FOR PHARMACEUTICAL COMPANIES, BY REGION, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 158
AI IN BIOTECHNOLOGY MARKET FOR BIOTECHNOLOGY COMPANIES, BY REGION, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 159
AI IN BIOTECHNOLOGY MARKET FOR BIOTECHNOLOGY COMPANIES, BY REGION, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 160
AI IN BIOTECHNOLOGY MARKET FOR RESEARCH INSTITUTES & LABS, BY REGION, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 161
AI IN BIOTECHNOLOGY MARKET FOR RESEARCH INSTITUTES & LABS, BY REGION, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 162
AI IN BIOTECHNOLOGY MARKET FOR HEALTHCARE PROVIDERS, BY REGION, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 163
AI IN BIOTECHNOLOGY MARKET FOR HEALTHCARE PROVIDERS, BY REGION, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 164
AI IN BIOTECHNOLOGY MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 165
AI IN BIOTECHNOLOGY MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 166
AI IN BIOTECHNOLOGY MARKET, BY REGION, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 167
AI IN BIOTECHNOLOGY MARKET, BY REGION, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 168
NORTH AMERICA: AI IN BIOTECHNOLOGY MARKET, BY COUNTRY, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 169
NORTH AMERICA: AI IN BIOTECHNOLOGY MARKET, BY COUNTRY, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 170
NORTH AMERICA: AI IN BIOTECHNOLOGY MARKET, BY OFFERING, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 171
NORTH AMERICA: AI IN BIOTECHNOLOGY MARKET, BY OFFERING, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 172
NORTH AMERICA: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 173
NORTH AMERICA: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 174
NORTH AMERICA: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 175
NORTH AMERICA: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 176
NORTH AMERICA: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT, BY TYPE, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 177
NORTH AMERICA: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT, BY TYPE, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 178
NORTH AMERICA: DRUG DISCOVERY MARKET, BY TYPE, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 179
NORTH AMERICA: DRUG DISCOVERY MARKET, BY TYPE, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 180
NORTH AMERICA: CLINICAL DEVELOPMENT MARKET, BY TYPE, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 181
NORTH AMERICA: CLINICAL DEVELOPMENT MARKET, BY TYPE, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 182
NORTH AMERICA: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN, BY TYPE, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 183
NORTH AMERICA: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN, BY TYPE, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 184
NORTH AMERICA: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL, BY TYPE, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 185
NORTH AMERICA: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL, BY TYPE, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 186
NORTH AMERICA: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT, BY TYPE, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 187
NORTH AMERICA: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT, BY TYPE, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 188
NORTH AMERICA: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE, BY TYPE, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 189
NORTH AMERICA: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE, BY TYPE, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 190
NORTH AMERICA: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 191
NORTH AMERICA: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 192
NORTH AMERICA: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 193
NORTH AMERICA: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 194
NORTH AMERICA: AI IN BIOTECHNOLOGY MARKET, BY END USER, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 195
NORTH AMERICA: AI IN BIOTECHNOLOGY MARKET, BY END USER, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 196
US: AI IN BIOTECHNOLOGY MARKET, BY OFFERING, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 197
US: AI IN BIOTECHNOLOGY MARKET, BY OFFERING, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 198
US: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 199
US: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 200
US: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 201
US: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 202
US: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT, BY TYPE, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 203
US: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT, BY TYPE, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 204
US: DRUG DISCOVERY MARKET, BY TYPE, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 205
US: DRUG DISCOVERY MARKET, BY TYPE, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 206
US: CLINICAL DEVELOPMENT MARKET, BY TYPE, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 207
US: CLINICAL DEVELOPMENT MARKET, BY TYPE, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 208
US: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN, BY TYPE, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 209
US: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN, BY TYPE, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 210
US: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL, BY TYPE, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 211
US: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL, BY TYPE, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 212
US: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT, BY TYPE, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 213
US: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT, BY TYPE, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 214
US: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE, BY TYPE, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 215
US: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE, BY TYPE, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 216
US: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 217
US: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 218
US: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 219
US: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 220
US: AI IN BIOTECHNOLOGY MARKET, BY END USER, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 221
US: AI IN BIOTECHNOLOGY MARKET, BY END USER, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 222
CANADA: AI IN BIOTECHNOLOGY MARKET, BY OFFERING, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 223
CANADA: AI IN BIOTECHNOLOGY MARKET, BY OFFERING, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 224
CANADA: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 225
CANADA: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 226
CANADA: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 227
CANADA: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 228
CANADA: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT, BY TYPE, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 229
CANADA: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT, BY TYPE, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 230
CANADA: DRUG DISCOVERY MARKET, BY TYPE, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 231
CANADA: DRUG DISCOVERY MARKET, BY TYPE, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 232
CANADA: CLINICAL DEVELOPMENT MARKET, BY TYPE, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 233
CANADA: CLINICAL DEVELOPMENT MARKET, BY TYPE, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 234
CANADA: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN, BY TYPE, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 235
CANADA: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN, BY TYPE, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 236
CANADA: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL, BY TYPE, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 237
CANADA: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL, BY TYPE, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 238
CANADA: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT, BY TYPE, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 239
CANADA: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT, BY TYPE, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 240
CANADA: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE, BY TYPE, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 241
CANADA: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE, BY TYPE, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 242
CANADA: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 243
CANADA: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 244
CANADA: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 245
CANADA: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 246
CANADA: AI IN BIOTECHNOLOGY MARKET, BY END USER, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 247
CANADA: AI IN BIOTECHNOLOGY MARKET, BY END USER, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 248
EUROPE: AI IN BIOTECHNOLOGY MARKET, BY COUNTRY, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 249
EUROPE: AI IN BIOTECHNOLOGY MARKET, BY COUNTRY, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 250
EUROPE: AI IN BIOTECHNOLOGY MARKET, BY OFFERING, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 251
EUROPE: AI IN BIOTECHNOLOGY MARKET, BY OFFERING, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 252
EUROPE: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 253
EUROPE: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 254
EUROPE: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 255
EUROPE: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 256
EUROPE: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT, BY TYPE, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 257
EUROPE: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT, BY TYPE, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 258
EUROPE: DRUG DISCOVERY MARKET, BY TYPE, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 259
EUROPE: DRUG DISCOVERY MARKET, BY TYPE, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 260
EUROPE: CLINICAL DEVELOPMENT MARKET, BY TYPE, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 261
EUROPE: CLINICAL DEVELOPMENT MARKET, BY TYPE, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 262
EUROPE: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN, BY TYPE, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 263
EUROPE: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN, BY TYPE, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 264
EUROPE: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL, BY TYPE, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 265
EUROPE: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL, BY TYPE, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 266
EUROPE: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT, BY TYPE, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 267
EUROPE: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT, BY TYPE, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 268
EUROPE: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE, BY TYPE, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 269
EUROPE: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE, BY TYPE, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 270
EUROPE: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 271
EUROPE: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 272
EUROPE: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 273
EUROPE: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 274
EUROPE: AI IN BIOTECHNOLOGY MARKET, BY END USER, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 275
EUROPE: AI IN BIOTECHNOLOGY MARKET, BY END USER, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 276
GERMANY: AI IN BIOTECHNOLOGY MARKET, BY OFFERING, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 277
GERMANY: AI IN BIOTECHNOLOGY MARKET, BY OFFERING, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 278
GERMANY: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 279
GERMANY: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 280
GERMANY: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 281
GERMANY: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 282
GERMANY: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT, BY TYPE, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 283
GERMANY: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT, BY TYPE, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 284
GERMANY: DRUG DISCOVERY MARKET, BY TYPE, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 285
GERMANY: DRUG DISCOVERY MARKET, BY TYPE, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 286
GERMANY: CLINICAL DEVELOPMENT MARKET, BY TYPE, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 287
GERMANY: CLINICAL DEVELOPMENT MARKET, BY TYPE, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 288
GERMANY: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN, BY TYPE, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 289
GERMANY: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN, BY TYPE, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 290
GERMANY: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL, BY TYPE, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 291
GERMANY: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL, BY TYPE, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 292
GERMANY: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT, BY TYPE, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 293
GERMANY: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT, BY TYPE, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 294
GERMANY: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE, BY TYPE, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 295
GERMANY: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE, BY TYPE, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 296
GERMANY: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 297
GERMANY: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 298
GERMANY: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 299
GERMANY: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 300
GERMANY: AI IN BIOTECHNOLOGY MARKET, BY END USER, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 301
GERMANY: AI IN BIOTECHNOLOGY MARKET, BY END USER, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 302
UK: AI IN BIOTECHNOLOGY MARKET, BY OFFERING, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 303
UK: AI IN BIOTECHNOLOGY MARKET, BY OFFERING, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 304
UK: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 305
UK: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 306
UK: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 307
UK: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 308
UK: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT, BY TYPE, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 309
UK: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT, BY TYPE, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 310
UK: DRUG DISCOVERY MARKET, BY TYPE, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 311
UK: DRUG DISCOVERY MARKET, BY TYPE, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 312
UK: CLINICAL DEVELOPMENT MARKET, BY TYPE, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 313
UK: CLINICAL DEVELOPMENT MARKET, BY TYPE, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 314
UK: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN, BY TYPE, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 315
UK: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN, BY TYPE, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 316
UK: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL, BY TYPE, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 317
UK: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL, BY TYPE, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 318
UK: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT, BY TYPE, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 319
UK: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT, BY TYPE, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 320
UK: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE, BY TYPE, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 321
UK: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE, BY TYPE, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 322
UK: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 323
UK: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 324
UK: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 325
UK: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 326
UK: AI IN BIOTECHNOLOGY MARKET, BY END USER, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 327
UK: AI IN BIOTECHNOLOGY MARKET, BY END USER, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 328
FRANCE: AI IN BIOTECHNOLOGY MARKET, BY OFFERING, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 329
FRANCE: AI IN BIOTECHNOLOGY MARKET, BY OFFERING, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 330
FRANCE: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 331
FRANCE: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 332
FRANCE: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 333
FRANCE: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 334
FRANCE: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT, BY TYPE, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 335
FRANCE: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT, BY TYPE, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 336
FRANCE: DRUG DISCOVERY MARKET, BY TYPE, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 337
FRANCE: DRUG DISCOVERY MARKET, BY TYPE, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 338
FRANCE: CLINICAL DEVELOPMENT MARKET, BY TYPE, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 339
FRANCE: CLINICAL DEVELOPMENT MARKET, BY TYPE, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 340
FRANCE: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN, BY TYPE, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 341
FRANCE: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN, BY TYPE, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 342
FRANCE: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL, BY TYPE, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 343
FRANCE: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL, BY TYPE, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 344
FRANCE: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT, BY TYPE, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 345
FRANCE: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT, BY TYPE, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 346
FRANCE: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE, BY TYPE, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 347
FRANCE: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE, BY TYPE, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 348
FRANCE: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 349
FRANCE: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 350
FRANCE: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 351
FRANCE: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 352
FRANCE: AI IN BIOTECHNOLOGY MARKET, BY END USER, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 353
FRANCE: AI IN BIOTECHNOLOGY MARKET, BY END USER, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 354
ITALY: AI IN BIOTECHNOLOGY MARKET, BY OFFERING, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 355
ITALY: AI IN BIOTECHNOLOGY MARKET, BY OFFERING, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 356
ITALY: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 357
ITALY: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 358
ITALY: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 359
ITALY: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 360
ITALY: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT, BY TYPE, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 361
ITALY: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT, BY TYPE, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 362
ITALY: DRUG DISCOVERY MARKET, BY TYPE, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 363
ITALY: DRUG DISCOVERY MARKET, BY TYPE, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 364
ITALY: CLINICAL DEVELOPMENT MARKET, BY TYPE, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 365
ITALY: CLINICAL DEVELOPMENT MARKET, BY TYPE, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 366
ITALY: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN, BY TYPE, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 367
ITALY: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN, BY TYPE, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 368
ITALY: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL, BY TYPE, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 369
ITALY: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL, BY TYPE, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 370
ITALY: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT, BY TYPE, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 371
ITALY: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT, BY TYPE, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 372
ITALY: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE, BY TYPE, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 373
ITALY: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE, BY TYPE, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 374
ITALY: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 375
ITALY: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 376
ITALY: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 377
ITALY: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 378
ITALY: AI IN BIOTECHNOLOGY MARKET, BY END USER, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 379
ITALY: AI IN BIOTECHNOLOGY MARKET, BY END USER, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 380
SPAIN: AI IN BIOTECHNOLOGY MARKET, BY OFFERING, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 381
SPAIN: AI IN BIOTECHNOLOGY MARKET, BY OFFERING, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 382
SPAIN: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 383
SPAIN: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 384
SPAIN: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 385
SPAIN: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 386
SPAIN: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT, BY TYPE, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 387
SPAIN: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT, BY TYPE, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 388
SPAIN: DRUG DISCOVERY MARKET, BY TYPE, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 389
SPAIN: DRUG DISCOVERY MARKET, BY TYPE, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 390
SPAIN: CLINICAL DEVELOPMENT MARKET, BY TYPE, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 391
SPAIN: CLINICAL DEVELOPMENT MARKET, BY TYPE, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 392
SPAIN: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN, BY TYPE, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 393
SPAIN: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN, BY TYPE, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 394
SPAIN: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL, BY TYPE, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 395
SPAIN: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL, BY TYPE, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 396
SPAIN: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT, BY TYPE, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 397
SPAIN: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT, BY TYPE, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 398
SPAIN: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE, BY TYPE, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 399
SPAIN: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE, BY TYPE, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 400
SPAIN: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 401
SPAIN: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 402
SPAIN: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 403
SPAIN: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 404
SPAIN: AI IN BIOTECHNOLOGY MARKET, BY END USER, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 405
SPAIN: AI IN BIOTECHNOLOGY MARKET, BY END USER, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 406
REST OF EUROPE: AI IN BIOTECHNOLOGY MARKET, BY OFFERING, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 407
REST OF EUROPE: AI IN BIOTECHNOLOGY MARKET, BY OFFERING, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 408
REST OF EUROPE: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 409
REST OF EUROPE: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 410
REST OF EUROPE: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 411
REST OF EUROPE: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 412
REST OF EUROPE: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT, BY TYPE, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 413
REST OF EUROPE: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT, BY TYPE, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 414
REST OF EUROPE: DRUG DISCOVERY MARKET, BY TYPE, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 415
REST OF EUROPE: DRUG DISCOVERY MARKET, BY TYPE, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 416
REST OF EUROPE: CLINICAL DEVELOPMENT MARKET, BY TYPE, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 417
REST OF EUROPE: CLINICAL DEVELOPMENT MARKET, BY TYPE, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 418
REST OF EUROPE: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN, BY TYPE, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 419
REST OF EUROPE: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN, BY TYPE, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 420
REST OF EUROPE: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL, BY TYPE, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 421
REST OF EUROPE: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL, BY TYPE, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 422
REST OF EUROPE: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT, BY TYPE, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 423
REST OF EUROPE: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT, BY TYPE, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 424
REST OF EUROPE: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE, BY TYPE, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 425
REST OF EUROPE: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE, BY TYPE, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 426
REST OF EUROPE: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 427
REST OF EUROPE: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 428
REST OF EUROPE: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 429
REST OF EUROPE: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 430
REST OF EUROPE: AI IN BIOTECHNOLOGY MARKET, BY END USER, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 431
REST OF EUROPE: AI IN BIOTECHNOLOGY MARKET, BY END USER, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 432
ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET, BY COUNTRY, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 433
ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET, BY COUNTRY, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 434
ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET, BY OFFERING, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 435
ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET, BY OFFERING, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 436
ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 437
ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 438
ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 439
ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 440
ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT, BY TYPE, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 441
ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT, BY TYPE, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 442
ASIA PACIFIC: DRUG DISCOVERY MARKET, BY TYPE, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 443
ASIA PACIFIC: DRUG DISCOVERY MARKET, BY TYPE, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 444
ASIA PACIFIC: CLINICAL DEVELOPMENT MARKET, BY TYPE, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 445
ASIA PACIFIC: CLINICAL DEVELOPMENT MARKET, BY TYPE, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 446
ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN, BY TYPE, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 447
ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN, BY TYPE, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 448
ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL, BY TYPE, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 449
ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL, BY TYPE, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 450
ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT, BY TYPE, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 451
ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT, BY TYPE, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 452
ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE, BY TYPE, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 453
ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE, BY TYPE, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 454
ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 455
ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 456
ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 457
ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 458
ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET, BY END USER, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 459
ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET, BY END USER, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 460
JAPAN: AI IN BIOTECHNOLOGY MARKET, BY OFFERING, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 461
JAPAN: AI IN BIOTECHNOLOGY MARKET, BY OFFERING, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 462
JAPAN: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 463
JAPAN: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 464
JAPAN: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 465
JAPAN: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 466
JAPAN: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT, BY TYPE, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 467
JAPAN: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT, BY TYPE, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 468
JAPAN: DRUG DISCOVERY MARKET, BY TYPE, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 469
JAPAN: DRUG DISCOVERY MARKET, BY TYPE, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 470
JAPAN: CLINICAL DEVELOPMENT MARKET, BY TYPE, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 471
JAPAN: CLINICAL DEVELOPMENT MARKET, BY TYPE, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 472
JAPAN: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN, BY TYPE, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 473
JAPAN: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN, BY TYPE, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 474
JAPAN: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL, BY TYPE, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 475
JAPAN: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL, BY TYPE, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 476
JAPAN: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT, BY TYPE, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 477
JAPAN: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT, BY TYPE, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 478
JAPAN: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE, BY TYPE, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 479
JAPAN: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE, BY TYPE, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 480
JAPAN: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 481
JAPAN: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 482
JAPAN: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 483
JAPAN: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 484
JAPAN: AI IN BIOTECHNOLOGY MARKET, BY END USER, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 485
JAPAN: AI IN BIOTECHNOLOGY MARKET, BY END USER, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 486
CHINA: AI IN BIOTECHNOLOGY MARKET, BY OFFERING, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 487
CHINA: AI IN BIOTECHNOLOGY MARKET, BY OFFERING, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 488
CHINA: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 489
CHINA: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 490
CHINA: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 491
CHINA: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 492
CHINA: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT, BY TYPE, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 493
CHINA: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT, BY TYPE, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 494
CHINA: DRUG DISCOVERY MARKET, BY TYPE, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 495
CHINA: DRUG DISCOVERY MARKET, BY TYPE, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 496
CHINA: CLINICAL DEVELOPMENT MARKET, BY TYPE, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 497
CHINA: CLINICAL DEVELOPMENT MARKET, BY TYPE, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 498
CHINA: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN, BY TYPE, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 499
CHINA: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN, BY TYPE, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 500
CHINA: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL, BY TYPE, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 501
CHINA: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL, BY TYPE, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 502
CHINA: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT, BY TYPE, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 503
CHINA: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT, BY TYPE, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 504
CHINA: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE, BY TYPE, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 505
CHINA: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE, BY TYPE, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 506
CHINA: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 507
CHINA: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 508
CHINA: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 509
CHINA: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 510
CHINA: AI IN BIOTECHNOLOGY MARKET, BY END USER, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 511
CHINA: AI IN BIOTECHNOLOGY MARKET, BY END USER, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 512
INDIA: AI IN BIOTECHNOLOGY MARKET, BY OFFERING, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 513
INDIA: AI IN BIOTECHNOLOGY MARKET, BY OFFERING, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 514
INDIA: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 515
INDIA: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 516
INDIA: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 517
INDIA: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 518
INDIA: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT, BY TYPE, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 519
INDIA: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT, BY TYPE, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 520
INDIA: DRUG DISCOVERY MARKET, BY TYPE, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 521
INDIA: DRUG DISCOVERY MARKET, BY TYPE, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 522
INDIA: CLINICAL DEVELOPMENT MARKET, BY TYPE, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 523
INDIA: CLINICAL DEVELOPMENT MARKET, BY TYPE, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 524
INDIA: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN, BY TYPE, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 525
INDIA: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN, BY TYPE, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 526
INDIA: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL, BY TYPE, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 527
INDIA: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL, BY TYPE, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 528
INDIA: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT, BY TYPE, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 529
INDIA: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT, BY TYPE, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 530
INDIA: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE, BY TYPE, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 531
INDIA: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE, BY TYPE, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 532
INDIA: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 533
INDIA: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 534
INDIA: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 535
INDIA: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 536
INDIA: AI IN BIOTECHNOLOGY MARKET, BY END USER, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 537
INDIA: AI IN BIOTECHNOLOGY MARKET, BY END USER, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 538
SOUTH KOREA: AI IN BIOTECHNOLOGY MARKET, BY OFFERING, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 539
SOUTH KOREA: AI IN BIOTECHNOLOGY MARKET, BY OFFERING, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 540
SOUTH KOREA: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 541
SOUTH KOREA: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 542
SOUTH KOREA: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 543
SOUTH KOREA: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 544
SOUTH KOREA: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT, BY TYPE, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 545
SOUTH KOREA: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT, BY TYPE, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 546
SOUTH KOREA: DRUG DISCOVERY MARKET, BY TYPE, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 547
SOUTH KOREA: DRUG DISCOVERY MARKET, BY TYPE, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 548
SOUTH KOREA: CLINICAL DEVELOPMENT MARKET, BY TYPE, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 549
SOUTH KOREA: CLINICAL DEVELOPMENT MARKET, BY TYPE, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 550
SOUTH KOREA: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN, BY TYPE, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 551
SOUTH KOREA: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN, BY TYPE, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 552
SOUTH KOREA: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL, BY TYPE, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 553
SOUTH KOREA: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL, BY TYPE, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 554
SOUTH KOREA: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT, BY TYPE, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 555
SOUTH KOREA: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT, BY TYPE, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 556
SOUTH KOREA: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE, BY TYPE, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 557
SOUTH KOREA: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE, BY TYPE, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 558
SOUTH KOREA: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 559
SOUTH KOREA: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 560
SOUTH KOREA: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 561
SOUTH KOREA: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 562
SOUTH KOREA: AI IN BIOTECHNOLOGY MARKET, BY END USER, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 563
SOUTH KOREA: AI IN BIOTECHNOLOGY MARKET, BY END USER, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 564
AUSTRALIA: AI IN BIOTECHNOLOGY MARKET, BY OFFERING, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 565
AUSTRALIA: AI IN BIOTECHNOLOGY MARKET, BY OFFERING, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 566
AUSTRALIA: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 567
AUSTRALIA: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 568
AUSTRALIA: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 569
AUSTRALIA: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 570
AUSTRALIA: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT, BY TYPE, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 571
AUSTRALIA: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT, BY TYPE, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 572
AUSTRALIA: DRUG DISCOVERY MARKET, BY TYPE, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 573
AUSTRALIA: DRUG DISCOVERY MARKET, BY TYPE, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 574
AUSTRALIA: CLINICAL DEVELOPMENT MARKET, BY TYPE, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 575
AUSTRALIA: CLINICAL DEVELOPMENT MARKET, BY TYPE, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 576
AUSTRALIA: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN, BY TYPE, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 577
AUSTRALIA: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN, BY TYPE, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 578
AUSTRALIA: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL, BY TYPE, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 579
AUSTRALIA: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL, BY TYPE, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 580
AUSTRALIA: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT, BY TYPE, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 581
AUSTRALIA: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT, BY TYPE, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 582
AUSTRALIA: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE, BY TYPE, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 583
AUSTRALIA: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE, BY TYPE, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 584
AUSTRALIA: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 585
AUSTRALIA: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 586
AUSTRALIA: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 587
AUSTRALIA: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 588
AUSTRALIA: AI IN BIOTECHNOLOGY MARKET, BY END USER, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 589
AUSTRALIA: AI IN BIOTECHNOLOGY MARKET, BY END USER, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 590
REST OF ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET, BY OFFERING, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 591
REST OF ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET, BY OFFERING, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 592
REST OF ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 593
REST OF ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 594
REST OF ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 595
REST OF ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 596
REST OF ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT, BY TYPE, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 597
REST OF ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT, BY TYPE, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 598
REST OF ASIA PACIFIC: DRUG DISCOVERY MARKET, BY TYPE, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 599
REST OF ASIA PACIFIC: DRUG DISCOVERY MARKET, BY TYPE, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 600
REST OF ASIA PACIFIC: CLINICAL DEVELOPMENT MARKET, BY TYPE, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 601
REST OF ASIA PACIFIC: CLINICAL DEVELOPMENT MARKET, BY TYPE, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 602
REST OF ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN, BY TYPE, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 603
REST OF ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN, BY TYPE, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 604
REST OF ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL, BY TYPE, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 605
REST OF ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL, BY TYPE, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 606
REST OF ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT, BY TYPE, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 607
REST OF ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT, BY TYPE, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 608
REST OF ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE, BY TYPE, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 609
REST OF ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE, BY TYPE, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 610
REST OF ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 611
REST OF ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 612
REST OF ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 613
REST OF ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 614
REST OF ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET, BY END USER, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 615
REST OF ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET, BY END USER, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 616
LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET, BY COUNTRY, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 617
LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET, BY COUNTRY, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 618
LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET, BY OFFERING, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 619
LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET, BY OFFERING, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 620
LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 621
LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 622
LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 623
LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 624
LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT, BY TYPE, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 625
LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT, BY TYPE, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 626
LATIN AMERICA: DRUG DISCOVERY MARKET, BY TYPE, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 627
LATIN AMERICA: DRUG DISCOVERY MARKET, BY TYPE, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 628
LATIN AMERICA: CLINICAL DEVELOPMENT MARKET, BY TYPE, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 629
LATIN AMERICA: CLINICAL DEVELOPMENT MARKET, BY TYPE, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 630
LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN, BY TYPE, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 631
LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN, BY TYPE, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 632
LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL, BY TYPE, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 633
LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL, BY TYPE, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 634
LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT, BY TYPE, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 635
LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT, BY TYPE, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 636
LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE, BY TYPE, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 637
LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE, BY TYPE, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 638
LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 639
LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 640
LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 641
LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 642
LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET, BY END USER, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 643
LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET, BY END USER, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 644
BRAZIL: AI IN BIOTECHNOLOGY MARKET, BY OFFERING, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 645
BRAZIL: AI IN BIOTECHNOLOGY MARKET, BY OFFERING, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 646
BRAZIL: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 647
BRAZIL: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 648
BRAZIL: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 649
BRAZIL: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 650
BRAZIL: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT, BY TYPE, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 651
BRAZIL: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT, BY TYPE, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 652
BRAZIL: DRUG DISCOVERY MARKET, BY TYPE, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 653
BRAZIL: DRUG DISCOVERY MARKET, BY TYPE, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 654
BRAZIL: CLINICAL DEVELOPMENT MARKET, BY TYPE, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 655
BRAZIL: CLINICAL DEVELOPMENT MARKET, BY TYPE, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 656
BRAZIL: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN, BY TYPE, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 657
BRAZIL: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN, BY TYPE, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 658
BRAZIL: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL, BY TYPE, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 659
BRAZIL: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL, BY TYPE, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 660
BRAZIL: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT, BY TYPE, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 661
BRAZIL: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT, BY TYPE, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 662
BRAZIL: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE, BY TYPE, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 663
BRAZIL: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE, BY TYPE, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 664
BRAZIL: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 665
BRAZIL: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 666
BRAZIL: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 667
BRAZIL: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 668
BRAZIL: AI IN BIOTECHNOLOGY MARKET, BY END USER, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 669
BRAZIL: AI IN BIOTECHNOLOGY MARKET, BY END USER, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 670
MEXICO: AI IN BIOTECHNOLOGY MARKET, BY OFFERING, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 671
MEXICO: AI IN BIOTECHNOLOGY MARKET, BY OFFERING, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 672
MEXICO: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 673
MEXICO: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 674
MEXICO: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 675
MEXICO: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 676
MEXICO: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT, BY TYPE, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 677
MEXICO: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT, BY TYPE, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 678
MEXICO: DRUG DISCOVERY MARKET, BY TYPE, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 679
MEXICO: DRUG DISCOVERY MARKET, BY TYPE, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 680
MEXICO: CLINICAL DEVELOPMENT MARKET, BY TYPE, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 681
MEXICO: CLINICAL DEVELOPMENT MARKET, BY TYPE, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 682
MEXICO: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN, BY TYPE, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 683
MEXICO: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN, BY TYPE, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 684
MEXICO: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL, BY TYPE, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 685
MEXICO: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL, BY TYPE, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 686
MEXICO: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT, BY TYPE, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 687
MEXICO: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT, BY TYPE, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 688
MEXICO: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE, BY TYPE, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 689
MEXICO: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE, BY TYPE, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 690
MEXICO: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 691
MEXICO: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 692
MEXICO: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 693
MEXICO: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 694
MEXICO: AI IN BIOTECHNOLOGY MARKET, BY END USER, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 695
MEXICO: AI IN BIOTECHNOLOGY MARKET, BY END USER, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 696
REST OF LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET, BY OFFERING, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 697
REST OF LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET, BY OFFERING, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 698
REST OF LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 699
REST OF LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 700
REST OF LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 701
REST OF LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 702
REST OF LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT, BY TYPE, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 703
REST OF LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT, BY TYPE, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 704
REST OF LATIN AMERICA: DRUG DISCOVERY MARKET, BY TYPE, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 705
REST OF LATIN AMERICA: DRUG DISCOVERY MARKET, BY TYPE, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 706
REST OF LATIN AMERICA: CLINICAL DEVELOPMENT MARKET, BY TYPE, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 707
REST OF LATIN AMERICA: CLINICAL DEVELOPMENT MARKET, BY TYPE, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 708
REST OF LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN, BY TYPE, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 709
REST OF LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN, BY TYPE, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 710
REST OF LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL, BY TYPE, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 711
REST OF LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL, BY TYPE, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 712
REST OF LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT, BY TYPE, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 713
REST OF LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT, BY TYPE, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 714
REST OF LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE, BY TYPE, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 715
REST OF LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE, BY TYPE, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 716
REST OF LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 717
REST OF LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 718
REST OF LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 719
REST OF LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 720
REST OF LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET, BY END USER, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 721
REST OF LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET, BY END USER, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 722
MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET, BY REGION, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 723
MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET, BY REGION, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 724
MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET, BY OFFERING, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 725
MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET, BY OFFERING, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 726
MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 727
MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 728
MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 729
MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 730
MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT, BY TYPE, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 731
MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT, BY TYPE, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 732
MIDDLE EAST & AFRICA: DRUG DISCOVERY MARKET, BY TYPE, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 733
MIDDLE EAST & AFRICA: DRUG DISCOVERY MARKET, BY TYPE, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 734
MIDDLE EAST & AFRICA: CLINICAL DEVELOPMENT MARKET, BY TYPE, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 735
MIDDLE EAST & AFRICA: CLINICAL DEVELOPMENT MARKET, BY TYPE, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 736
MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN, BY TYPE, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 737
MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN, BY TYPE, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 738
MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL, BY TYPE, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 739
MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL, BY TYPE, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 740
MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT, BY TYPE, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 741
MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT, BY TYPE, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 742
MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE, BY TYPE, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 743
MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE, BY TYPE, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 744
MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 745
MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 746
MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 747
MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 748
MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET, BY END USER, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 749
MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET, BY END USER, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 750
GCC COUNTRIES: AI IN BIOTECHNOLOGY MARKET, BY OFFERING, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 751
GCC COUNTRIES: AI IN BIOTECHNOLOGY MARKET, BY OFFERING, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 752
GCC COUNTRIES: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 753
GCC COUNTRIES: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 754
GCC COUNTRIES: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 755
GCC COUNTRIES: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 756
GCC COUNTRIES: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT, BY TYPE, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 757
GCC COUNTRIES: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT, BY TYPE, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 758
GCC COUNTRIES: DRUG DISCOVERY MARKET, BY TYPE, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 759
GCC COUNTRIES: DRUG DISCOVERY MARKET, BY TYPE, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 760
GCC COUNTRIES: CLINICAL DEVELOPMENT MARKET, BY TYPE, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 761
GCC COUNTRIES: CLINICAL DEVELOPMENT MARKET, BY TYPE, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 762
GCC COUNTRIES: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN, BY TYPE, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 763
GCC COUNTRIES: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN, BY TYPE, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 764
GCC COUNTRIES: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL, BY TYPE, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 765
GCC COUNTRIES: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL, BY TYPE, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 766
GCC COUNTRIES: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT, BY TYPE, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 767
GCC COUNTRIES: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT, BY TYPE, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 768
GCC COUNTRIES: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE, BY TYPE, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 769
GCC COUNTRIES: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE, BY TYPE, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 770
GCC COUNTRIES: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 771
GCC COUNTRIES: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 772
GCC COUNTRIES: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 773
GCC COUNTRIES: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 774
GCC COUNTRIES: AI IN BIOTECHNOLOGY MARKET, BY END USER, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 775
GCC COUNTRIES: AI IN BIOTECHNOLOGY MARKET, BY END USER, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 776
REST OF MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET, BY OFFERING, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 777
REST OF MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET, BY OFFERING, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 778
REST OF MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 779
REST OF MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 780
REST OF MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 781
REST OF MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 782
REST OF MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT, BY TYPE, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 783
REST OF MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT, BY TYPE, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 784
REST OF MIDDLE EAST & AFRICA: DRUG DISCOVERY MARKET, BY TYPE, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 785
REST OF MIDDLE EAST & AFRICA: DRUG DISCOVERY MARKET, BY TYPE, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 786
REST OF MIDDLE EAST & AFRICA: CLINICAL DEVELOPMENT MARKET, BY TYPE, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 787
REST OF MIDDLE EAST & AFRICA: CLINICAL DEVELOPMENT MARKET, BY TYPE, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 788
REST OF MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN, BY TYPE, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 789
REST OF MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN, BY TYPE, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 790
REST OF MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL, BY TYPE, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 791
REST OF MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL, BY TYPE, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 792
REST OF MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT, BY TYPE, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 793
REST OF MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT, BY TYPE, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 794
REST OF MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE, BY TYPE, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 795
REST OF MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE, BY TYPE, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 796
REST OF MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 797
REST OF MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 798
REST OF MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 799
REST OF MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 800
REST OF MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET, BY END USER, 2023–2029 (USD MILLION)
 
 
 
 
 
 
TABLE 801
REST OF MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET, BY END USER, 2030–2035 (USD MILLION)
 
 
 
 
 
 
TABLE 802
OVERVIEW OF STRATEGIES DEPLOYED BY KEY PLAYERS IN AI IN BIOTECHNOLOGY MARKET, JANUARY 2022–NOVEMBER 2025
 
 
 
 
 
 
TABLE 803
AI IN BIOTECHNOLOGY MARKET: DEGREE OF COMPETITION
 
 
 
 
 
 
TABLE 804
AI IN BIOTECHNOLOGY: REGION FOOTPRINT
 
 
 
 
 
 
TABLE 805
AI IN BIOTECHNOLOGY MARKET: COMPONENT FOOTPRINT
 
 
 
 
 
 
TABLE 806
AI IN BIOTECHNOLOGY MARKET: FUNCTION FOOTPRINT
 
 
 
 
 
 
TABLE 807
AI IN BIOTECHNOLOGY MARKET: END-USER FOOTPRINT
 
 
 
 
 
 
TABLE 808
AI IN BIOTECHNOLOGY MARKET: DETAILED LIST OF KEY STARTUPS/SME PLAYERS
 
 
 
 
 
 
TABLE 809
AI IN BIOTECHNOLOGY MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SME PLAYERS, BY OFFERING, FUNCTION, END USER, AND REGION
 
 
 
 
 
 
TABLE 810
AI IN BIOTECHNOLOGY MARKET: PRODUCT LAUNCHES & UPGRADES, JANUARY 2022–NOVEMBER 2025
 
 
 
 
 
 
TABLE 811
AI IN BIOTECHNOLOGY MARKET: DEALS, JANUARY 2022–NOVEMBER 2025
 
 
 
 
 
 
TABLE 812
AI IN BIOTECHNOLOGY MARKET: EXPANSIONS, JANUARY 2022–NOVEMBER 2025
 
 
 
 
 
 
TABLE 813
NVIDIA CORPORATION: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 814
NVIDIA CORPORATION: PRODUCTS OFFERED
 
 
 
 
 
 
TABLE 815
NVIDIA CORPORATION: PRODUCT LAUNCHES, JANUARY 2022−NOVEMBER 2025
 
 
 
 
 
 
TABLE 816
NVIDIA CORPORATION: DEALS, JANUARY 2022−NOVEMBER 2025
 
 
 
 
 
 
TABLE 817
ILLUMINA, INC.: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 818
ILLUMINA, INC.: PRODUCTS OFFERED
 
 
 
 
 
 
TABLE 819
ILLUMINA, INC.: PRODUCT LAUNCHES, JANUARY 2022−NOVEMBER 2025
 
 
 
 
 
 
TABLE 820
ILLUMINA, INC.: DEALS, JANUARY 2022−NOVEMBER 2025
 
 
 
 
 
 
TABLE 821
RECURSION: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 822
RECURSION: PRODUCTS OFFERED
 
 
 
 
 
 
TABLE 823
RECURSION: PRODUCT LAUNCHES, JANUARY 2022−NOVEMBER 2025
 
 
 
 
 
 
TABLE 824
RECURSION: DEALS, JANUARY 2022−NOVEMBER 2025
 
 
 
 
 
 
TABLE 825
RECURSION: EXPANSIONS, JANUARY 2022−NOVEMBER 2025
 
 
 
 
 
 
TABLE 826
RECURSION: OTHER DEVELOPMENTS, JANUARY 2022−NOVEMBER 2025
 
 
 
 
 
 
TABLE 827
SCHRÖDINGER, INC.: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 828
SCHRÖDINGER, INC.: PRODUCTS OFFERED
 
 
 
 
 
 
TABLE 829
SCHRÖDINGER, INC.: PRODUCT UPGRADES, JANUARY 2022−NOVEMBER 2025
 
 
 
 
 
 
TABLE 830
SCHRÖDINGER, INC.: DEALS, JANUARY 2022−NOVEMBER 2025
 
 
 
 
 
 
TABLE 831
SCHRÖDINGER, INC.: OTHER DEVELOPMENTS, JANUARY 2022−NOVEMBER 2025
 
 
 
 
 
 
TABLE 832
BENEVOLENTAI: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 833
BENEVOLENTAI: PRODUCTS OFFERED
 
 
 
 
 
 
TABLE 834
BENEVOLENTAI: DEALS, JANUARY 2022−NOVEMBER 2025
 
 
 
 
 
 
TABLE 835
BENEVOLENTAI: OTHER DEVELOPMENTS, JANUARY 2022−NOVEMBER 2025
 
 
 
 
 
 
TABLE 836
DATA4CURE, INC.: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 837
DATA4CURE, INC.: PRODUCTS OFFERED
 
 
 
 
 
 
TABLE 838
DATA4CURE, INC.: DEALS, JANUARY 2022–NOVEMBER 2025
 
 
 
 
 
 
TABLE 839
QIAGEN: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 840
QIAGEN: PRODUCTS OFFERED
 
 
 
 
 
 
TABLE 841
QIAGEN: PRODUCT LAUNCHES AND ENHANCEMENTS, JANUARY 2022−NOVEMBER 2025
 
 
 
 
 
 
TABLE 842
QIAGEN: DEALS, JANUARY 2022−NOVEMBER 2025
 
 
 
 
 
 
TABLE 843
INSILICO MEDICINE: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 844
INSILICO MEDICINE: PRODUCTS OFFERED
 
 
 
 
 
 
TABLE 845
INSILICO MEDICINE: PRODUCT LAUNCHES, APPROVALS, AND ENHANCEMENTS, JANUARY 2022–NOVEMBER 2025
 
 
 
 
 
 
TABLE 846
INSILICO MEDICINE: DEALS, JANUARY 2022–NOVEMBER 2025
 
 
 
 
 
 
TABLE 847
INSILICO MEDICINE: OTHER DEVELOPMENTS, JANUARY 2022–NOVEMBER 2025
 
 
 
 
 
 
TABLE 848
DNANEXUS, INC.: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 849
DNANEXUS, INC.: PRODUCTS OFFERED
 
 
 
 
 
 
TABLE 850
DNANEXUS, INC.: DEALS, JANUARY 2022−NOVEMBER 2025
 
 
 
 
 
 
TABLE 851
DNANEXUS, INC.: OTHER DEVELOPMENTS, JANUARY 2022−NOVEMBER 2025
 
 
 
 
 
 
TABLE 852
TEMPUS: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 853
TEMPUS: PRODUCTS OFFERED
 
 
 
 
 
 
TABLE 854
TEMPUS: PRODUCT APPROVALS, JANUARY 2022–NOVEMBER 2025
 
 
 
 
 
 
TABLE 855
TEMPUS: DEALS, JANUARY 2022−NOVEMBER 2025
 
 
 
 
 
 
TABLE 856
TEMPUS: OTHER DEVELOPMENTS, JANUARY 2022−NOVEMBER 2025
 
 
 
 
 
 
TABLE 857
SOPHIA GENETICS: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 858
SOPHIA GENETICS: PRODUCTS OFFERED
 
 
 
 
 
 
TABLE 859
SOPHIA GENETICS: PRODUCT LAUNCHES, JANUARY 2022−NOVEMBER 2025
 
 
 
 
 
 
TABLE 860
SOPHIA GENETICS: DEALS, JANUARY 2022−NOVEMBER 2025
 
 
 
 
 
 
TABLE 861
SOPHIA GENETICS: OTHER DEVELOPMENTS, JANUARY 2022−NOVEMBER 2025
 
 
 
 
 
 
TABLE 862
PREDICTIVE ONCOLOGY: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 863
PREDICTIVE ONCOLOGY: PRODUCTS OFFERED
 
 
 
 
 
 
TABLE 864
PREDICTIVE ONCOLOGY: PRODUCT LAUNCHES, JANUARY 2022−NOVEMBER 2025
 
 
 
 
 
 
TABLE 865
PREDICTIVE ONCOLOGY: DEALS, JANUARY 2022−NOVEMBER 2025
 
 
 
 
 
 
TABLE 866
PREDICTIVE ONCOLOGY: EXPANSIONS, JANUARY 2022−NOVEMBER 2025
 
 
 
 
 
 
TABLE 867
DEEP GENOMICS: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 868
DEEP GENOMICS: PRODUCTS OFFERED
 
 
 
 
 
 
TABLE 869
DEEP GENOMICS: PRODUCT LAUNCHES, JANUARY 2022−NOVEMBER 2025
 
 
 
 
 
 
TABLE 870
NUMEDII, INC.: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 871
NUMEDII, INC.: PRODUCTS OFFERED
 
 
 
 
 
 
TABLE 872
XTALPI INC.: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 873
XTALPI INC.: PRODUCTS OFFERED
 
 
 
 
 
 
TABLE 874
XTALPI INC.: DEALS, JANUARY 2022−NOVEMBER 2025
 
 
 
 
 
 
TABLE 875
IKTOS: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 876
IKTOS: PRODUCTS OFFERED
 
 
 
 
 
 
TABLE 877
IKTOS: PRODUCT LAUNCHES, JANUARY 2022−NOVEMBER 2025
 
 
 
 
 
 
TABLE 878
IKTOS: DEALS, JANUARY 2022−NOVEMBER 2025
 
 
 
 
 
 
TABLE 879
IKTOS: OTHER DEVELOPMENTS, JANUARY 2022−NOVEMBER 2025
 
 
 
 
 
 
TABLE 880
BPGBIO, INC.: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 881
BPGBIO, INC.: PRODUCTS OFFERED
 
 
 
 
 
 
TABLE 882
BPGBIO, INC.: PRODUCT LAUNCHES, JANUARY 2022−NOVEMBER 2025
 
 
 
 
 
 
TABLE 883
BPGBIO, INC.: DEALS, JANUARY 2022−NOVEMBER 2025
 
 
 
 
 
 
TABLE 884
BPGBIO, INC.: OTHER DEVELOPMENTS, JANUARY 2022−NOVEMBER 2025
 
 
 
 
 
 
TABLE 885
EUROFINS DISCOVERY: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 886
EUROFINS DISCOVERY: PRODUCTS OFFERED
 
 
 
 
 
 
TABLE 887
EUROFINS DISCOVERY: PRODUCT LAUNCHES, JANUARY 2022−NOVEMBER 2025
 
 
 
 
 
 
TABLE 888
EUROFINS DISCOVERY: DEALS, JANUARY 2022−NOVEMBER 2025
 
 
 
 
 
 
TABLE 889
EUROFINS DISCOVERY: EXPANSIONS, JANUARY 2022−NOVEMBER 2025
 
 
 
 
 
 
TABLE 890
VERISIM LIFE: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 891
LIFEBIT BIOTECH INC.: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 892
VALO HEALTH: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 893
VERGE GENOMICS: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 894
LOGICA: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 895
AMERICAN CHEMICAL SOCIETY: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 896
AGANITHA AI INC.: COMPANY OVERVIEW
 
 
 
 
 
 
LIST OF FIGURES
 
 
 
 
 
 
 
FIGURE 1
AI IN BIOTECHNOLOGY MARKET SEGMENTATION & REGIONAL SCOPE
 
 
 
 
 
 
FIGURE 2
AI IN BIOTECHNOLOGY MARKET: YEARS CONSIDERED
 
 
 
 
 
 
FIGURE 3
RESEARCH DESIGN
 
 
 
 
 
 
FIGURE 4
PRIMARY SOURCES
 
 
 
 
 
 
FIGURE 5
BREAKDOWN OF PRIMARY INTERVIEWS (DEMAND-SIDE): BY COMPANY, DESIGNATION, AND REGION
 
 
 
 
 
 
FIGURE 6
MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS
 
 
 
 
 
 
FIGURE 7
TOP-DOWN APPROACH
 
 
 
 
 
 
FIGURE 8
AI IN BIOTECHNOLOGY MARKET: CAGR PROJECTIONS
 
 
 
 
 
 
FIGURE 9
CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
 
 
 
 
 
 
FIGURE 10
DATA TRIANGULATION
 
 
 
 
 
 
FIGURE 11
AI IN BIOTECHNOLOGY MARKET, BY OFFERING, 2025 VS. 2035 (USD MILLION)
 
 
 
 
 
 
FIGURE 12
AI IN BIOTECHNOLOGY MARKET, BY FUNCTION, 2025 VS. 2035 (USD MILLION)
 
 
 
 
 
 
FIGURE 13
AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE, 2025 VS. 2035 (USD MILLION)
 
 
 
 
 
 
FIGURE 14
AI IN BIOTECHNOLOGY MARKET, BY END USER, 2025 VS. 2035 (USD MILLION)
 
 
 
 
 
 
FIGURE 15
AI IN BIOTECHNOLOGY MARKET: REGIONAL SNAPSHOT
 
 
 
 
 
 
FIGURE 16
FOCUS ON COST-EFFECTIVE PROCESSES AND FAVORABLE GOVERNMENT FUNDING TO DRIVE MARKET
 
 
 
 
 
 
FIGURE 17
NORTH AMERICA TO DOMINATE AI IN BIOTECHNOLOGY MARKET DURING STUDY PERIOD
 
 
 
 
 
 
FIGURE 18
END-TO-END SOLUTIONS AND US COMMANDED LARGEST NORTH AMERICAN MARKET SHARE IN 2024
 
 
 
 
 
 
FIGURE 19
INDIA TO REGISTER HIGHEST CAGR DURING FORECAST PERIOD
 
 
 
 
 
 
FIGURE 20
EMERGING ECONOMIES TO REGISTER HIGHER GROWTH RATES FROM 2025 TO 2035
 
 
 
 
 
 
FIGURE 21
AI IN BIOTECHNOLOGY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
 
 
 
 
 
 
FIGURE 22
EVOLUTION OF AI IN BIOTECHNOLOGY MARKET
 
 
 
 
 
 
FIGURE 23
AI IN BIOTECHNOLOGY MARKET: PORTER’S FIVE FORCES ANALYSIS
 
 
 
 
 
 
FIGURE 24
AI IN BIOTECHNOLOGY MARKET: VALUE CHAIN ANALYSIS
 
 
 
 
 
 
FIGURE 25
AI IN BIOTECHNOLOGY MARKET: ECOSYSTEM ANALYSIS
 
 
 
 
 
 
FIGURE 26
TRENDS AND DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
 
 
 
 
 
 
FIGURE 27
AI IN BIOTECHNOLOGY MARKET: INVESTMENT AND FUNDING SCENARIO
 
 
 
 
 
 
FIGURE 28
AI IN BIOTECHNOLOGY MARKET: PATENT PUBLICATION TRENDS, 2015–2025
 
 
 
 
 
 
FIGURE 29
JURISDICTION AND TOP APPLICANT ANALYSIS, 2015–2025
 
 
 
 
 
 
FIGURE 30
AI IN BIOTECHNOLOGY MARKET: PATENT ANALYSIS, JANUARY 2015–JANUARY 2025
 
 
 
 
 
 
FIGURE 31
MARKET POTENTIAL OF AI/GENERATIVE AI ON AI IN BIOTECHNOLOGY SOLUTIONS
 
 
 
 
 
 
FIGURE 32
INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF TOP THREE END USERS
 
 
 
 
 
 
FIGURE 33
KEY BUYING CRITERIA FOR TOP THREE END USERS
 
 
 
 
 
 
FIGURE 34
NUMBER OF AI-DISCOVERED MOLECULES IN CLINICAL TRIALS, 2019–2023
 
 
 
 
 
 
FIGURE 35
NORTH AMERICA: AI IN BIOTECHNOLOGY MARKET SNAPSHOT
 
 
 
 
 
 
FIGURE 36
ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET SNAPSHOT
 
 
 
 
 
 
FIGURE 37
REVENUE ANALYSIS OF KEY PLAYERS IN AI IN BIOTECHNOLOGY MARKET, 2020–2024 (USD BILLION)
 
 
 
 
 
 
FIGURE 38
MARKET SHARE ANALYSIS OF KEY PLAYERS IN AI IN BIOTECHNOLOGY MARKET (2024)
 
 
 
 
 
 
FIGURE 39
RANKING OF KEY PLAYERS IN AI IN BIOTECHNOLOGY MARKET (2024)
 
 
 
 
 
 
FIGURE 40
AI IN BIOTECHNOLOGY MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2024
 
 
 
 
 
 
FIGURE 41
AI IN BIOTECHNOLOGY MARKET: COMPANY FOOTPRINT
 
 
 
 
 
 
FIGURE 42
AI IN BIOTECHNOLOGY MARKET: COMPANY EVALUATION MATRIX (START-UPS/SMES), 2024
 
 
 
 
 
 
FIGURE 43
EV/EBITDA OF KEY VENDORS
 
 
 
 
 
 
FIGURE 44
YEAR-TO-DATE (YTD) PRICE, TOTAL RETURN, AND 5-YEAR STOCK BETA OF AI IN BIOTECHNOLOGY SOLUTION VENDORS
 
 
 
 
 
 
FIGURE 45
AI IN BIOTECHNOLOGY MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS
 
 
 
 
 
 
FIGURE 46
NVIDIA CORPORATION: COMPANY SNAPSHOT
 
 
 
 
 
 
FIGURE 47
ILLUMINA, INC.: COMPANY SNAPSHOT
 
 
 
 
 
 
FIGURE 48
RECURSION: COMPANY SNAPSHOT
 
 
 
 
 
 
FIGURE 49
SCHRÖDINGER, INC.: COMPANY SNAPSHOT
 
 
 
 
 
 
FIGURE 50
BENEVOLENTAI: COMPANY SNAPSHOT
 
 
 
 
 
 
FIGURE 51
QIAGEN: COMPANY SNAPSHOT
 
 
 
 
 
 
FIGURE 52
SOPHIA GENETICS: COMPANY SNAPSHOT
 
 
 
 
 
 
FIGURE 53
PREDICTIVE ONCOLOGY: COMPANY SNAPSHOT
 
 
 
 
 
 
FIGURE 54
XTALPI INC.: COMPANY SNAPSHOT
 
 
 
 
 
 
FIGURE 55
EUROFINS DISCOVERY: COMPANY SNAPSHOT
 
 
 
 
 
 

Methodology

This market research study primarily relied on secondary sources, directories, and databases to collect information for this technical, market-oriented, and financial analysis of the AI in biotechnology market. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives from major market players, and industry consultants, among others, to gather and verify critical qualitative and quantitative data and assess market prospects. The size of the AI in biotechnology market was estimated using multiple secondary research methods and confirmed with inputs from primary research to determine the final market size.

Secondary Research

The secondary research process involved extensively using secondary sources, including directories, databases (such as Bloomberg Businessweek, Factiva, and D&B Hoovers), white papers, annual reports, company house documents, investor presentations, and SEC filings of companies. Some non-exclusive secondary sources include the World Health Organization (WHO), the Organization for Economic Co-operation and Development (OECD), Healthcare Information and Management Systems Society (HIMSS), Centers for Disease Control and Prevention (CDC), ClinicalTrials.gov, expert interviews, and MarketsandMarkets analysis.

Secondary research was conducted to gather information for the detailed, technical, market-focused, and commercial analysis of the AI in biotechnology market. It was also used to collect key information about major players, market classification, and segmentation based on industry trends, down to the most detailed level, along with significant developments related to market and technology perspectives. Additionally, a database of leading industry players was compiled using secondary research.

Primary Research

During the primary research process, various sources from both the supply and demand sides were interviewed to gather qualitative and quantitative information for this report. Primary sources mainly include industry experts from core and related industries, preferred suppliers, manufacturers, distributors, technology developers, researchers, and organizations involved in all segments of this industry’s value chain. In-depth interviews were conducted with various primary respondents, such as key industry participants, subject-matter experts (SMEs), C-level executives of leading market players, and industry consultants, among other specialists, to obtain and verify critical qualitative and quantitative information as well as assess prospects.

Primary research was conducted to identify segmentation types, industry trends, key players, and key market dynamics such as drivers, restraints, opportunities, challenges, and strategies adopted by key players.

After completing the market engineering process- which includes calculations for market statistics, market breakdown, size estimations, forecasting, and data triangulation- extensive primary research was carried out. This research aimed to gather information and verify the key numbers obtained during the market analysis. Additionally, primary research was used to identify different types of market segmentation, analyze industry trends, evaluate the competitive landscape of AI solutions for biotechnology offered by various players, and understand key market dynamics such as drivers, restraints, opportunities, challenges, industry trends, and strategies employed by key market players.

In the complete market engineering process, the top-down and bottom-up approaches, along with several data triangulation methods, were extensively used to estimate and forecast the market segments and subsegments listed in this report. Extensive qualitative and quantitative analysis was conducted on the entire market engineering process to identify key information and insights throughout the report.

Breakdown of Primary Interviews

AI in Biotechnology Market

Note 1: Others include sales, marketing, and product managers.

Note 2: Tiers are defined based on a company’s total revenue, as of 2024: Tier 1 = >USD 1 billion, Tier 2 = USD 500 million to USD 1 billion, and Tier 3 = < USD 500 million.

To know about the assumptions considered for the study, download the pdf brochure

Market Size Estimation

The market size estimates and forecasts in this study are based on a combination of the bottom-up approach (revenue share analysis of leading players) and the top-down approach (evaluation of utilization, adoption, and penetration trends by offering, function, deployment mode, end user, and region).

AI in Biotechnology Market

Data Triangulation

After determining the overall market size from the estimation process described above, the market for AI in biotechnology was divided into various segments and subsegments. To finalize the overall market analysis and obtain accurate statistics for all segments and subsegments, data triangulation and market breakdown techniques were used whenever applicable. The data was cross-verified by examining different factors and trends from both the demand and supply sides of the market for AI in biotechnology.

Market Definition

The AI in biotechnology market includes technologies that use artificial intelligence to advance drug discovery, genomics, and personalized medicine. This market is defined by the growing utilization of machine learning and data analytics to improve research and development efficiency.

Stakeholders

  • Healthcare IT service providers
  • Pharmaceutical/Biopharmaceutical companies
  • Biotechnology firms
  • AI technology providers
  • Academic & research institutions
  • Academic medical centers/universities/hospitals
  • Regulatory agencies
  • Clinical research organizations (CROs)
  • Genomic testing labs
  • Government agencies
  • Startups in AI and biotech
  • Pharmaceutical supply chain partners
  • Consulting firms
  • Clinical trial management system providers
  • Bioinformatics companies
  • Advocacy groups
  • Investors & financial institutions

Report Objectives

  • To define, describe, and forecast the AI in biotechnology market by offering, function, deployment mode, end user, and region
  • To provide detailed information regarding the major drivers, restraints, opportunities, and challenges influencing market growth
  • To strategically analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall AI in biotechnology market
  • To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
  • To forecast the size of the AI in biotechnology market in five main regions (and their respective countries): North America, Europe, Asia Pacific, the Middle East & Africa, and Latin America
  • To provide key industry insights, such as value chain, regulatory, patent, and recession impact analysis
  • To profile the key players in the market and comprehensively analyze their core competencies
  • To track and analyze competitive developments, such as product launches & upgrades, collaborations, partnerships, acquisitions, investments, contracts, agreements, alliances, mergers, funding, and expansions of the leading players in the market
  • To benchmark players within the market using the company evaluation matrix, which analyzes market players on various parameters within the broad categories of business strategy, market share, and product offering

TABLE OF CONTENTS

METHODOLOGY

Need a Tailored Report?

Customize this report to your needs

Get 10% FREE Customization

Customize This Report
Fact checked
Cite this Research

Personalize This Research

  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
Request A Free Customisation

Let Us Help You

  • What are the Known and Unknown Adjacencies Impacting the AI in Biotechnology Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
Customized Workshop Request
Forbes

Custom Market Research Services

We Will Customise The Research For You, In Case The Report Listed Above Does Not Meet With Your Requirements

Get 10% Free Customisation

Growth opportunities and latent adjacency in AI in Biotechnology Market

DMCA.com Protection Status